=== МЕТАДАННЫЕ ===
{
  "original_filename": "Vascular Toxicities of Cancer Therapies_ 2025 Update _ Arteriosclerosis, Thrombosis, and Vascular Biology.html",
  "converted_date": "2026-01-31T14:51:23.574230",
  "file_size_bytes": 895696,
  "original_format": "html",
  "document_type": "Articles",
  "source_folder": "Articles",
  "full_path": "00_RAW_CARDIOLOGY/Articles/Vascular Toxicities of Cancer Therapies_ 2025 Update _ Arteriosclerosis, Thrombosis, and Vascular Biology.html"
}

=== СОДЕРЖАНИЕ ===
Vascular Toxicities of Cancer Therapies: 2025 Update | Arteriosclerosis, Thrombosis, and Vascular Biology
Skip to main content
Advertisement
Become a memberVolunteerDonate
JournalsBrowseCollectionsSubjectsAHA Journal PodcastsTrend WatchResourcesCMEAHA Journals @ MeetingsJournal MetricsEarly Career ResourcesInformationFor AuthorsFor ReviewersFor SubscribersFor International UsersAlerts
Shopping cart with
0
item
Cart
Search
Sign in
REGISTER
Quick Search in JournalsEnter search termQuick Search anywhereEnter search termQuick search in CitationsJournalYearVolumeIssuePageSearching:This JournalThis JournalAnywhereCitation
Advanced Search
Search
navigate the sidebar menu
Sign in
REGISTER
Quick Search anywhereEnter search term
Publications
Arteriosclerosis, Thrombosis, and Vascular Biology
Current Issue
Archive
Journal Information
About ATVB
Author
Instructions
Editorial
Board
Meet the Editors
Information for
Advertisers
Features
ATVB_net Blog
ATVB In Focus
Lecture Series
Reviews
Early Career
Resources
ATVB Journal
Awards
Circulation
Circulation Research
Hypertension
Stroke
Journal of the American Heart Association
Circulation: Arrhythmia and Electrophysiology
Circulation: Cardiovascular Imaging
Circulation: Cardiovascular Interventions
Circulation: Population Health and Outcomes
Circulation: Genomic and Precision Medicine
Circulation: Heart Failure
Stroke: Vascular and Interventional Neurology
Annals of Internal Medicine: Clinical Cases
Information
For Authors
For Reviewers
For Subscribers
For International Users
Submit & Publish
Submit to the AHA
Editorial Policies
Open Science
Value of Many Voices
Publishing with the AHA
Open Access Information
Resources
AHA Journals CME
AHA Journals @ Meetings
Metrics
AHA Journals Podcast Network
Early Career Resources
Trend Watch
Professional Heart Daily
AHA Newsroom
Current Issue
Archive
Journal Information
About ATVB
Author
Instructions
Editorial
Board
Meet the Editors
Information for
Advertisers
Features
ATVB_net Blog
ATVB In Focus
Lecture Series
Reviews
Early Career
Resources
ATVB Journal
Awards
Submit
Reference #1
Review ArticleOriginally Published 11 December 2025Vascular Toxicities of Cancer Therapies: 2025 UpdateTeodora Donisan, Dinu V. Balanescu, Jun-ichi Abe https://orcid.org/0000-0001-7439-7774, Amir Lerman https://orcid.org/0000-0002-9446-5313, Cezar A. Iliescu https://orcid.org/0000-0002-8817-4579, and Joerg Herrmann https://orcid.org/0000-0001-6675-4559 herrmann.joerg@mayo.eduAuthor Info & AffiliationsArteriosclerosis, Thrombosis, and Vascular BiologyVolume 46, Number 2https://doi.org/10.1161/ATVBAHA.125.319867
214MetricsTotal Downloads214Last 12 Months214View all metrics
Track CitationsAdd to favorites
Get AccessContentsAbstractGraphical AbstractReferenceseLettersInformation & AuthorsMetrics & CitationsGet AccessReferencesFiguresTablesMediaShareAbstractAdvances in cancer therapies have transformed many malignancies into chronic or manageable conditions, but have been linked to adverse, including cardiovascular, events. Vascular toxicities associated with cancer treatment range from abnormal vasoreactivity to accelerated atherosclerosis, arterial thrombotic events, vasculitis, and arterial aneurysms or dissections. 5-fluorouracil and VEGF (vascular endothelial growth factor) inhibitors are the agents most commonly linked to abnormal vasoreactivity, whereas BCR-ABL (breakpoint cluster region–Abelson murine leukemia viral oncogene homolog) inhibitors and immune checkpoint inhibitors have been associated with accelerated atherosclerosis. Arterial thrombotic events are seen with VEGF and BCR-ABL inhibitors as well as platinum drugs. Vasculitis emerged with the use of immune checkpoint inhibitors, and arterial aneurysms and dissections with VEGF inhibitors. Radiation therapy can lead to several of the outlined vascular toxicities. This review comprehensively explores the mechanisms of vascular complications associated with chemotherapy, targeted therapies, immunotherapies, and radiation therapy. Key contributors include endothelial injury and dysfunction, oxidative stress, and inflammation. An understanding of the mechanisms of vascular toxicities may facilitate optimal treatment and preventive strategies in patients with cancer.Graphical AbstractOpen in ViewerGet full access to this articleView all available purchase options and get full access to this article.Get AccessAlready a Subscriber? Sign in as an individual or via your institutionReferences1.Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol. 2020;17:503–522. doi: 10.1038/s41569-020-0347-2CrossrefPubMedGoogle Scholar2.Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N. Cancer therapy-associated thrombosis. Arterioscler Thromb Vasc Biol. 2021;41:1291–1305. doi: 10.1161/ATVBAHA.120.314378CrossrefPubMedGoogle Scholar3.Südhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, Schmiegel W. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15:661–664. doi: 10.1093/annonc/mdh150CrossrefPubMedGoogle Scholar4.Hammond ST, Baumfalk DR, Parr SK, Butenas ALE, Scheuermann BC, Turpin VG, Behnke BJ, Hashmi MH, Ade CJ. Impaired microvascular reactivity in patients treated with 5-fluorouracil chemotherapy regimens: potential role of endothelial dysfunction. Int J Cardiol Heart Vasc. 2023;49:101300. doi: 10.1016/j.ijcha.2023.101300CrossrefPubMedGoogle Scholar5.Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974–984. doi: 10.1016/j.ctrv.2013.03.005CrossrefPubMedGoogle Scholar6.Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134:75–82. doi: 10.1007/s00432-007-0250-9CrossrefPubMedGoogle Scholar7.Zafar A, Drobni ZD, Lei M, Gongora CA, Quinaglia T, Lou UY, Mosarla R, Murphy SP, Jones-O’Connor M, Mahmood A, et al. The efficacy and safety of cardio-protective therapy in patients with 5-FU (fluorouracil)-associated coronary vasospasm. PLoS One. 2022;17:e0265767. doi: 10.1371/journal.pone.0265767CrossrefPubMedGoogle Scholar8.Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer. 2005;41:1542–1546. doi: 10.1016/j.ejca.2005.03.027CrossrefPubMedGoogle Scholar9.Yung LT, McCrea WA. Capecitabine induced acute coronary syndrome. BMJ Case Rep. 2009;2009:bcr09.2008.0964. doi: 10.1136/bcr.09.2008.0964CrossrefPubMedGoogle Scholar10.Kobayashi N, Hata N, Yokoyama S, Shinada T, Shirakabe A, Mizuno K. A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. J Nippon Med Sch. 2009;76:27–33. doi: 10.1272/jnms.76.27CrossrefPubMedGoogle Scholar11.Thijs AMJ, van Herpen CML, Sweep FCGJ, Geurts-Moespot A, Smits P, van der Graaf WTA, Rongen GA. Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans. Hypertension. 2013;61:1060–1065. doi: 10.1161/HYPERTENSIONAHA.111.00841CrossrefPubMedGoogle Scholar12.Chintalgattu V, Rees ML, Culver JC, Goel A, Jiffar T, Zhang J, Dunner K, Pati S, Bankson JA, Pasqualini R, et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 2013;5:187ra169. doi: 10.1126/scitranslmed.3005066CrossrefGoogle Scholar13.Sen F, Yildiz I, Basaran M, Ekenel M, Oz F, Kilic L, Toz B, Gurdal A, Camlica H, Bavbek S, et al. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib. J BUON. 2013;18:775–781.PubMedGoogle Scholar14.Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz. 2011;36:348–351. doi: 10.1007/s00059-011-3444-5CrossrefPubMedGoogle Scholar15.Kabir R, Vasquez N, Keshvani N, Vongpatanasin W. A case of chemotherapy-induced coronary vasospasm in a patient with colorectal cancer. J Cardiol Cases. 2020;22:117–120. doi: 10.1016/j.jccase.2020.05.014CrossrefPubMedGoogle Scholar16.Lim DH, Yoon JH, Jun DW, Lee OY, Yoon BC, Lee HR, Kim KS, Choi HS. Recurrent coronary artery vasospasm in a patient with hepatocellular carcinoma treated with sorafenib: a case report and literature review. J Liver Cancer. 2020;20:67–71. doi: 10.17998/jlc.20.1.67CrossrefPubMedGoogle Scholar17.Arima Y, Oshima S, Noda K, Fukushima H, Taniguchi I, Nakamura S, Shono M, Ogawa H. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol. 2009;54:512–515. doi: 10.1016/j.jjcc.2009.03.009CrossrefPubMedGoogle Scholar18.Hansen SW, Olsen N, Rossing N, Rørth M. Vascular toxicity and the mechanism underlying Raynaud’s phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Ann Oncol. 1990;1:289–292. doi: 10.1093/oxfordjournals.annonc.a057750CrossrefPubMedGoogle Scholar19.Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993;53:3028–3033.PubMedGoogle Scholar20.Otsu K, Tajiri K, Sakai S, Ieda M. Vasospastic angina following immune checkpoint blockade. Eur Heart J. 2020;41:1702. doi: 10.1093/eurheartj/ehz796CrossrefPubMedGoogle Scholar21.Kumamoto T, Kawano H, Kurobe M, Akashi R, Yonekura T, Ikeda S, Maemura K. Vasospastic angina: an immune-related adverse event. Intern Med. 2022;61:1983–1986. doi: 10.2169/internalmedicine.8540-21CrossrefPubMedGoogle Scholar22.Tao JJ, Roszkowska N, Majure DT, Mahmood SS. Coronary vasospasm during infusion of CD-19 directed chimeric antigen receptor T-cell therapy: a case report. Eur Heart J Case Rep. 2023;7:ytad342. doi: 10.1093/ehjcr/ytad342CrossrefPubMedGoogle Scholar23.Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, et al; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–2801. doi: 10.1093/eurheartj/ehw211CrossrefPubMedGoogle Scholar24.Beckman JA, Thakore A, Kalinowski BH, Harris JR, Creager MA. Radiation therapy impairs endothelium-dependent vasodilation in humans. J Am Coll Cardiol. 2001;37:761–765. doi: 10.1016/s0735-1097(00)01190-6CrossrefPubMedGoogle Scholar25.Kabir J, Lobo M, Zachary I. Staurosporine induces endothelial cell apoptosis via focal adhesion kinase dephosphorylation and focal adhesion disassembly independent of focal adhesion kinase proteolysis. Biochem J. 2002;367:145–155. doi: 10.1042/BJ20020665CrossrefPubMedGoogle Scholar26.Altieri P, Murialdo R, Barisione C, Lazzarini E, Garibaldi S, Fabbi P, Ruggeri C, Borile S, Carbone F, Armirotti A, et al. 5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1. Br J Pharmacol. 2017;174:3713–3726. doi: 10.1111/bph.13725CrossrefPubMedGoogle Scholar27.Schäfer A, Burkhardt M, Vollkommer T, Bauersachs J, Münzel T, Walter U, Smolenski A. Endothelium-dependent and -independent relaxation and VASP serines 157/239 phosphorylation by cyclic nucleotide-elevating vasodilators in rat aorta. Biochem Pharmacol. 2003;65:397–405. doi: 10.1016/s0006-2952(02)01523-xCrossrefPubMedGoogle Scholar28.Reiser J, Sever S, Faul C. Signal transduction in podocytes--spotlight on receptor tyrosine kinases. Nat Rev Nephrol. 2014;10:104–115. doi: 10.1038/nrneph.2013.274CrossrefPubMedGoogle Scholar29.Roskoski R. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007;356:323–328. doi: 10.1016/j.bbrc.2007.02.156CrossrefPubMedGoogle Scholar30.Barandier C, Ming XF, Rusconi S, Yang Z. PKC is required for activation of ROCK by RhoA in human endothelial cells. Biochem Biophys Res Commun. 2003;304:714–719. doi: 10.1016/s0006-291x(03)00668-5CrossrefPubMedGoogle Scholar31.Bárány K, Polyák E, Bárány M. Involvement of calponin and caldesmon in sustained contraction of arterial smooth muscle. Biochem Biophys Res Commun. 1992;187:847–852. doi: 10.1016/0006-291x(92)91274-tCrossrefPubMedGoogle Scholar32.Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14:7272–7283. doi: 10.1158/1078-0432.CCR-08-0652CrossrefPubMedGoogle Scholar33.Mongiardi MP, Radice G, Piras M, Stagni V, Pacioni S, Re A, Putti S, Ferrè F, Farsetti A, Pallini R, et al. Axitinib exposure triggers endothelial cells senescence through ROS accumulation and ATM activation. Oncogene. 2019;38:5413–5424. doi: 10.1038/s41388-019-0798-2CrossrefPubMedGoogle Scholar34.Winnik S, Lohmann C, Siciliani G, von Lukowicz T, Kuschnerus K, Kraenkel N, Brokopp CE, Enseleit F, Michels S, Ruschitzka F, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety. Int J Cardiol. 2013;168:2453–2461. doi: 10.1016/j.ijcard.2013.03.010CrossrefPubMedGoogle Scholar35.Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, Burstein HJ, Beckman JA. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension. 2011;58:85–92. doi: 10.1161/HYPERTENSIONAHA.110.168120CrossrefPubMedGoogle Scholar36.Alanazi WA, Alanazi AS, El-Nagar DM, Aljuraybah AM, Alsanea S, Alharbi M. Mechanism underlying triple VEGFR inhibitor tivozanib-induced hypertension in mice model. Pharmaceuticals (Basel). 2023;16:295. doi: 10.3390/ph16020295CrossrefPubMedGoogle Scholar37.Szczepaniak P, Siedlinski M, Hodorowicz-Zaniewska D, Nosalski R, Mikolajczyk TP, Dobosz AM, Dikalova A, Dikalov S, Streb J, Gara K, et al. Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism. J Clin Invest. 2022;132:e149117. doi: 10.1172/JCI149117CrossrefPubMedGoogle Scholar38.Sugimoto M, Nakayama M, Goto TM, Amano M, Komori K, Kaibuchi K. Rho-kinase phosphorylates eNOS at threonine 495 in endothelial cells. Biochem Biophys Res Commun. 2007;361:462–467. doi: 10.1016/j.bbrc.2007.07.030CrossrefPubMedGoogle Scholar39.Duquaine D, Hirsch GA, Chakrabarti A, Han Z, Kehrer C, Brook R, Joseph J, Schott A, Kalyanaraman B, Vasquez-Vivar J, et al. Rapid-onset endothelial dysfunction with Adriamycin: evidence for a dysfunctional nitric oxide synthase. Vasc Med. 2003;8:101–107. doi: 10.1191/1358863x03vm476oaCrossrefPubMedGoogle Scholar40.Cappetta D, De Angelis A, Sapio L, Prezioso L, Illiano M, Quaini F, Rossi F, Berrino L, Naviglio S, Urbanek K. Oxidative stress and cellular response to doxorubicin: a common factor in the complex milieu of anthracycline cardiotoxicity. Oxid Med Cell Longev. 2017;2017:1521020. doi: 10.1155/2017/1521020CrossrefPubMedGoogle Scholar41.Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. doi: 10.1016/j.biopha.2021.111708CrossrefPubMedGoogle Scholar42.Vásquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA, Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 1997;36:11293–11297. doi: 10.1021/bi971475eCrossrefPubMedGoogle Scholar43.Hader SN, Zinkevich N, Norwood Toro LE, Kriegel AJ, Kong A, Freed JK, Gutterman DD, Beyer AM. Detrimental effects of chemotherapy on human coronary microvascular function. Am J Physiol Heart Circ Physiol. 2019;317:H705–H710. doi: 10.1152/ajpheart.00370.2019CrossrefPubMedGoogle Scholar44.Galán-Arriola C, Vílchez-Tschischke JP, Lobo M, López GJ, de Molina-Iracheta A, Pérez-Martínez C, Villena-Gutiérrez R, Macías A, Díaz-Rengifo IA, Oliver E, et al. Coronary microcirculation damage in anthracycline cardiotoxicity. Cardiovasc Res. 2022;118:531–541. doi: 10.1093/cvr/cvab053CrossrefPubMedGoogle Scholar45.Menendez JC, Casanova D, Amado JA, Salas E, García-Unzueta MT, Fernandez F, de la Lastra LP, Berrazueta JR. Effects of radiation on endothelial function. Int J Radiat Oncol Biol Phys. 1998;41:905–913. doi: 10.1016/s0360-3016(98)00112-6CrossrefPubMedGoogle Scholar46.Baselet B, Sonveaux P, Baatout S, Aerts A. Pathological effects of ionizing radiation: endothelial activation and dysfunction. Cell Mol Life Sci. 2019;76:699–728. doi: 10.1007/s00018-018-2956-zCrossrefPubMedGoogle Scholar47.Jones P, Benghuzzi H, Tucci M, Richards L, Harrison G, Patel R. Pathophysiological changes associated with multiple exposure of ionizing radiation on MRC-5 cells in culture. Biomed Sci Instrum. 2007;43:254–259.PubMedGoogle Scholar48.Collins-Underwood JR, Zhao W, Sharpe JG, Robbins ME. NADPH oxidase mediates radiation-induced oxidative stress in rat brain microvascular endothelial cells. Free Radic Biol Med. 2008;45:929–938. doi: 10.1016/j.freeradbiomed.2008.06.024CrossrefPubMedGoogle Scholar49.Atochin DN, Wang A, Liu VW, Critchlow JD, Dantas AP, Looft-Wilson R, Murata T, Salomone S, Shin HK, Ayata C, et al. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J Clin Invest. 2007;117:1961–1967. doi: 10.1172/JCI29877CrossrefPubMedGoogle Scholar50.Hosoi Y, Yamamoto M, Ono T, Sakamoto K. Prostacyclin production in cultured endothelial cells is highly sensitive to low doses of ionizing radiation. Int J Radiat Biol. 1993;63:631–638. doi: 10.1080/09553009314450821CrossrefPubMedGoogle Scholar51.Soloviev AI, Tishkin SM, Parshikov AV, Ivanova IV, Goncharov EV, Gurney AM. Mechanisms of endothelial dysfunction after ionized radiation: selective impairment of the nitric oxide component of endothelium-dependent vasodilation. Br J Pharmacol. 2003;138:837–844. doi: 10.1038/sj.bjp.0705079CrossrefPubMedGoogle Scholar52.Lanza V, Fadda P, Iannone C, Negri R. Low-dose ionizing radiation stimulates transcription and production of endothelin by human vein endothelial cells. Radiat Res. 2007;168:193–198. doi: 10.1667/RR0780.1CrossrefPubMedGoogle Scholar53.Lanza V, Pretazzoli V, Olivieri G, Pascarella G, Panconesi A, Negri R. Transcriptional response of human umbilical vein endothelial cells to low doses of ionizing radiation. J Radiat Res. 2005;46:265–276. doi: 10.1269/jrr.46.265CrossrefPubMedGoogle Scholar54.Fardid R, Najafi M, Salajegheh A, Kazemi E, Rezaeyan A. Radiation-induced non-targeted effect in vivo: evaluation of cyclooygenase-2 and endothelin-1 gene expression in rat heart tissues. J Cancer Res Ther. 2017;13:51–55. doi: 10.4103/0973-1482.203601CrossrefPubMedGoogle Scholar55.Merlin SL, Brock GB, Begin LR, Hiou Tim FF, Macramalla AN, Seyam RM, Shenouda G, Dion SB. New insights into the role of endothelin-1 in radiation-associated impotence. Int J Impot Res. 2001;13:104–109. doi: 10.1038/sj.ijir.3900652CrossrefPubMedGoogle Scholar56.Papapetropoulos A, Burch SE, Topouzis S, Catravas JD. Radiation-induced alterations in angiotensin converting enzyme activity in cultured bovine pulmonary arterial endothelial cell monolayers. Toxicol Appl Pharmacol. 1993;120:96–105. doi: 10.1006/taap.1993.1091CrossrefPubMedGoogle Scholar57.Wei J, Xu H, Liu Y, Li B, Zhou F. Effect of captopril on radiation-induced TGF-β1 secretion in EA.Hy926 human umbilical vein endothelial cells. Oncotarget. 2017;8:20842–20850. doi: 10.18632/oncotarget.15356CrossrefPubMedGoogle Scholar58.Ward WF, Kim YT, Molteni A, Solliday NH. Radiation-induced pulmonary endothelial dysfunction in rats: modification by an inhibitor of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys. 1988;15:135–140. doi: 10.1016/0360-3016(88)90357-4CrossrefPubMedGoogle Scholar59.Cao S, Wu R. Expression of angiotensin II and aldosterone in radiation-induced lung injury. Cancer Biol Med. 2012;9:254–260. doi: 10.7497/j.issn.2095-3941.2012.04.006CrossrefPubMedGoogle Scholar60.Gajdusek CM, Tian H, London S, Zhou D, Rasey J, Mayberg MR. Gamma radiation effect on vascular smooth muscle cells in culture. Int J Radiat Oncol Biol Phys. 1996;36:821–828. doi: 10.1016/s0360-3016(96)00297-0CrossrefPubMedGoogle Scholar61.Keller PF, Verin V, Ziegler T, Mermillod B, Popowski Y, Delafontaine P. Gamma-irradiation markedly inhibits the hydrated collagen gel contradiction by arterial smooth muscle cells. J Investig Med. 2001;49:258–264. doi: 10.2310/6650.2001.33970CrossrefPubMedGoogle Scholar62.Heckenkamp J, Nigri GR, Waterman PR, Overhaus M, Kossodo SC, Lamuraglia GM. Gamma-irradiation modulates vascular smooth muscle cell and extracellular matrix function: implications for neointimal development. J Vasc Surg. 2004;39:1097–1103. doi: 10.1016/j.jvs.2003.12.021CrossrefPubMedGoogle Scholar63.Soloviev A, Tishkin S, Ivanova I, Zelensky S, Dosenko V, Kyrychenko S, Moreland RS. Functional and molecular consequences of ionizing irradiation on large conductance Ca2+-activated K+ channels in rat aortic smooth muscle cells. Life Sci. 2009;84:164–171. doi: 10.1016/j.lfs.2008.11.015CrossrefPubMedGoogle Scholar64.Soloviev AI, Tishkin SM, Zelensky SN, Ivanova IV, Kizub IV, Pavlova AA, Moreland RS. Ionizing radiation alters myofilament calcium sensitivity in vascular smooth muscle: potential role of protein kinase C. Am J Physiol Regul Integr Comp Physiol. 2005;289:R755–R762. doi: 10.1152/ajpregu.00748.2004CrossrefPubMedGoogle Scholar65.Roveri A, Coassin M, Maiorino M, Zamburlini A, van Amsterdam FT, Ratti E, Ursini F. Effect of hydrogen peroxide on calcium homeostasis in smooth muscle cells. Arch Biochem Biophys. 1992;297:265–270. doi: 10.1016/0003-9861(92)90671-iCrossrefPubMedGoogle Scholar66.Satoh K, Nigro P, Berk BC. Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin A. Antioxid Redox Signal. 2010;12:675–682. doi: 10.1089/ars.2009.2875CrossrefPubMedGoogle Scholar67.Ruef J, Rao GN, Li F, Bode C, Patterson C, Bhatnagar A, Runge MS. Induction of rat aortic smooth muscle cell growth by the lipid peroxidation product 4-hydroxy-2-nonenal. Circulation. 1998;97:1071–1078. doi: 10.1161/01.cir.97.11.1071CrossrefPubMedGoogle Scholar68.Rao GN, Alexander RW, Runge MS. Linoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-Fos, c-Jun, and c-Myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest. 1995;96:842–847. doi: 10.1172/JCI118130CrossrefPubMedGoogle Scholar69.Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, Valent P. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533–539. doi: 10.1002/ajh.22037CrossrefPubMedGoogle Scholar70.Dahlén T, Edgren G, Lambe M, Höglund M, Björkholm M, Sandin F, Själander A, Richter J, Olsson-Strömberg U, Ohm L, et al; Swedish CML Group and the Swedish CML Register Group. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med. 2016;165:161–166. doi: 10.7326/M15-2306CrossrefPubMedGoogle Scholar71.Saglio G, le Coutre P, Cortes J, Mayer J, Rowlings P, Mahon FX, Kroog G, Gooden K, Subar M, Shah NP. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Ann Hematol. 2017;96:1303–1313. doi: 10.1007/s00277-017-3012-zCrossrefPubMedGoogle Scholar72.Ali EA, Patel N, Khalid M, Kaddoura R, Kalavar M, Shani J, Yassin M. Myocardial infarction in chronic myeloid leukemia: results from the nationwide readmission database. Oncology (Huntingt). 2024;102:944–951. doi: 10.1159/000539149CrossrefGoogle Scholar73.Brümmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, Garcia-Gutierrez V, Chuah C, Kota V, Lipton JH, et al; BFORE study investigators. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36:1825–1833. doi: 10.1038/s41375-022-01589-yCrossrefPubMedGoogle Scholar74.Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, Smith BD, Ernst T, Giraldo-Castellano P, Olsson-Strömberg U, Saussele S, et al; BYOND Study Investigators. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34:2125–2137. doi: 10.1038/s41375-020-0915-9CrossrefPubMedGoogle Scholar75.Nicolini FE, Gagnieu M-C, Heiblig M, Blond E, Legros L, Guillermin Y, Morisset S, Barraco F, Etienne M, Le Borgne O, et al. Cardio-vascular events occurring on ponatinib in chronic phase chronic myeloid leukemia patients, preliminary analysis of a multicenter cohort. Blood. 2013;122:4020–4020. doi: 10.1182/blood.v122.21.4020.4020CrossrefGoogle Scholar76.Punwani N. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391:2275. doi: 10.1056/NEJMc2412813CrossrefPubMedGoogle Scholar77.Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617–626. doi: 10.1038/s41375-023-01829-9CrossrefPubMedGoogle Scholar78.Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, et al. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024;38:1522–1533. doi: 10.1038/s41375-024-02278-8CrossrefPubMedGoogle Scholar79.Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023;37:1048–1059. doi: 10.1038/s41375-023-01860-wCrossrefPubMedGoogle Scholar80.Luna A, Pérez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuño C, Vega MM, Alvarez-Larrán A, Salamanca A, García-Noblejas A, et al. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Ann Hematol. 2022;101:2263–2270. doi: 10.1007/s00277-022-04932-6CrossrefPubMedGoogle Scholar81.Pantaleo MA, Mandrioli A, Saponara M, Nannini M, Erente G, Lolli C, Biasco G. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012;12:231. doi: 10.1186/1471-2407-12-231CrossrefPubMedGoogle Scholar82.Cho JH, Won H, Lee W-S, Kim S-W, Hwang IG. Rapid progression of coronary atherosclerosis in patients taking an oral antitumor, multikinase receptor inhibitor. Circ Cardiovasc Interv. 2021;14:e010705. doi: 10.1161/CIRCINTERVENTIONS.121.010705CrossrefPubMedGoogle Scholar83.Sudasena D, Balanescu DV, Donisan T, Hassan S, Palaskas N, Kim P, Karimzad K, Lopez-Mattei J, Arain S, Gould KL, et al. Fulminant vascular and cardiac toxicity associated with tyrosine kinase inhibitor sorafenib. Cardiovasc Toxicol. 2019;19:382–387. doi: 10.1007/s12012-018-9499-2CrossrefPubMedGoogle Scholar84.Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142:2299–2311. doi: 10.1161/CIRCULATIONAHA.120.049981CrossrefPubMedGoogle Scholar85.Drobni ZD, Gongora C, Taron J, Suero-Abreu GA, Karady J, Gilman HK, Supraja S, Nikolaidou S, Leeper N, Merkely B, et al. Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer. J ImmunoTher Cancer. 2023;11:e007307. doi: 10.1136/jitc-2023-007307CrossrefPubMedGoogle Scholar86.Cheng SW, Ting AC, Ho P, Wu LL. Accelerated progression of carotid stenosis in patients with previous external neck irradiation. J Vasc Surg. 2004;39:409–415. doi: 10.1016/j.jvs.2003.08.031CrossrefPubMedGoogle Scholar87.Texakalidis P, Giannopoulos S, Tsouknidas I, Song S, Rivet DJ, Reiter ER, Reavey-Cantwell J. Prevalence of carotid stenosis following radiotherapy for head and neck cancer: a systematic review and meta-analysis. Head Neck. 2020;42:1077–1088. doi: 10.1002/hed.26102CrossrefPubMedGoogle Scholar88.Raghunathan D, Khilji MI, Hassan SA, Yusuf SW. Radiation-induced cardiovascular disease. Curr Atheroscler Rep. 2017;19:22. doi: 10.1007/s11883-017-0658-xCrossrefPubMedGoogle Scholar89.Pereira Lima MN, Biolo A, Foppa M, da Rosa PR, Rohde LE, Clausell N. A prospective, comparative study on the early effects of local and remote radiation therapy on carotid intima-media thickness and vascular cellular adhesion molecule-1 in patients with head and neck and prostate tumors. Radiother Oncol. 2011;101:449–453. doi: 10.1016/j.radonc.2010.03.026CrossrefPubMedGoogle Scholar90.Yakupovich A, Davison MA, Kharouta MZ, Turian J, Seder CW, Batus M, Fogg LF, Kalra D, Kosinski M, Taskesen T, et al. Heart dose and coronary artery calcification in patients receiving thoracic irradiation for lung cancer. J Thorac Dis. 2020;12:223–231. doi: 10.21037/jtd.2020.01.52CrossrefPubMedGoogle Scholar91.Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–998. doi: 10.1056/NEJMoa1209825CrossrefPubMedGoogle Scholar92.Abu Rmilah A, Adham A, Ikram-Ul H, Alzu’bi H, Nandan A, Jouni H, Hirashi S, Owen D, Deswal A, Lin SH, et al. Novel risk score for predicting acute cardiovascular and cerebrovascular events after chest radiotherapy in patients with breast or lung cancer [published online October 25, 2024]. Eur J Prev Cardiol. doi: 10.1093/eurjpc/zwae323. https://doi.org/10.1093/eurjpc/zwae323Google Scholar93.Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, et al. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 2017;31:2388–2397. doi: 10.1038/leu.2017.245CrossrefPubMedGoogle Scholar94.Maurizot A, Beressi JP, Manéglier B, de la Marre NH, Spentchian M, Soury P, Solvet-Sebire P, Collet-Gaudillat C, Baud JM, Livarek B, et al. Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion. Blood Cancer J. 2014;4:e247. doi: 10.1038/bcj.2014.66CrossrefPubMedGoogle Scholar95.Fuster JJ, Walsh K. Somatic mutations and clonal hematopoiesis: unexpected potential new drivers of age-related cardiovascular disease. Circ Res. 2018;122:523–532. doi: 10.1161/CIRCRESAHA.117.312115CrossrefPubMedGoogle Scholar96.Natarajan P, Jaiswal S, Kathiresan S. Clonal hematopoiesis: somatic mutations in blood cells and atherosclerosis. Circ Genom Precis Med. 2018;11:e001926. doi: 10.1161/CIRCGEN.118.001926CrossrefPubMedGoogle Scholar97.Ebert BL, Libby P. Clonal hematopoiesis confers predisposition to both cardiovascular disease and cancer: a newly recognized link between two major killers. Ann Intern Med. 2018;169:116–117. doi: 10.7326/M18-0737CrossrefPubMedGoogle Scholar98.Fernando F, Andres MS, Claudiani S, Kermani NZ, Ceccarelli G, Innes AJ, Khan A, Rosen SD, Apperley JF, Lyon AR, et al. Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score. Cardiooncology. 2024;10:42. doi: 10.1186/s40959-024-00245-xCrossrefPubMedGoogle Scholar99.Gover-Proaktor A, Granot G, Shapira S, Raz O, Pasvolsky O, Nagler A, Lev DL, Inbal A, Lubin I, Raanani P, et al. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma. 2017;58:1455–1467. doi: 10.1080/10428194.2016.1239258CrossrefPubMedGoogle Scholar100.Pinheiro EA, DeKeyser JM, Lenny B, Sapkota Y, Burridge PW. Nilotinib-induced alterations in endothelial cell function recapitulate clinical vascular phenotypes independent of ABL1. Sci Rep. 2024;14:7123. doi: 10.1038/s41598-024-57686-8CrossrefPubMedGoogle Scholar101.Detriche G, Zhang Y, Esposito B, Rea D, Messas E, Mirault T, Ait Oufella H. P3110Tyrosine kinase inhibitor nilotinib increases atherosclerosis burden in ApoE knock-out mice. Eur Heart J. 2019;40:ehz745.0185. doi: 10.1093/eurheartj/ehz745.0185CrossrefGoogle Scholar102.Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002;8:831–840. doi: 10.1038/nm731CrossrefPubMedGoogle Scholar103.Van der Veken B, De Meyer GRY, Martinet W. Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice. Vascul Pharmacol. 2018;100:34–40. doi: 10.1016/j.vph.2017.10.004CrossrefPubMedGoogle Scholar104.Newman JL, Stone JR. Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis. Cardiovasc Pathol. 2019;43:107148. doi: 10.1016/j.carpath.2019.107148CrossrefPubMedGoogle Scholar105.Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest. 2007;117:2974–2982. doi: 10.1172/JCI31344CrossrefPubMedGoogle Scholar106.Bu DX, Tarrio M, Maganto-Garcia E, Stavrakis G, Tajima G, Lederer J, Jarolim P, Freeman GJ, Sharpe AH, Lichtman AH. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:1100–1107. doi: 10.1161/ATVBAHA.111.224709CrossrefPubMedGoogle Scholar107.Weyand CM, Berry GJ, Goronzy JJ. The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease. J Leukoc Biol. 2018;103:565–575. doi: 10.1189/jlb.3MA0717-283CrossrefPubMedGoogle Scholar108.Ewing MM, Karper JC, Abdul S, de Jong RC, Peters HA, de Vries MR, Redeker A, Kuiper J, Toes RE, Arens R, et al. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int J Cardiol. 2013;168:1965–1974. doi: 10.1016/j.ijcard.2012.12.085CrossrefPubMedGoogle Scholar109.Matsumoto T, Sasaki N, Yamashita T, Emoto T, Kasahara K, Mizoguchi T, Hayashi T, Yodoi K, Kitano N, Saito T, et al. Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2016;36:1141–1151. doi: 10.1161/ATVBAHA.115.306848CrossrefPubMedGoogle Scholar110.Venkatesulu BP, Mahadevan LS, Aliru ML, Yang X, Bodd MH, Singh PK, Yusuf SW, Abe JI, Krishnan S. Radiation-induced endothelial vascular injury: a review of possible mechanisms. JACC Basic Transl Sci. 2018;3:563–572. doi: 10.1016/j.jacbts.2018.01.014CrossrefPubMedGoogle Scholar111.Stewart FA, Seemann I, Hoving S, Russell NS. Understanding radiation-induced cardiovascular damage and strategies for intervention. Clin Oncol (R Coll Radiol). 2013;25:617–624. doi: 10.1016/j.clon.2013.06.012CrossrefPubMedGoogle Scholar112.Stewart FA, Heeneman S, Te Poele J, Kruse J, Russell NS, Gijbels M, Daemen M. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE−/− mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. Am J Pathol. 2006;168:649–658. doi: 10.2353/ajpath.2006.050409CrossrefPubMedGoogle Scholar113.Hoving S, Heeneman S, Gijbels MJ, te Poele JA, Russell NS, Daemen MJ, Stewart FA. Single-dose and fractionated irradiation promote initiation and progression of atherosclerosis and induce an inflammatory plaque phenotype in ApoE(−/−) mice. Int J Radiat Oncol Biol Phys. 2008;71:848–857. doi: 10.1016/j.ijrobp.2008.02.031CrossrefPubMedGoogle Scholar114.Hoving S, Heeneman S, Gijbels MJ, te Poele JA, Pol JF, Gabriels K, Russell NS, Daemen MJ, Stewart FA. Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice. Radiother Oncol. 2011;101:100–108. doi: 10.1016/j.radonc.2011.09.019CrossrefPubMedGoogle Scholar115.Hoving S, Heeneman S, Gijbels MJ, te Poele JA, Bolla M, Pol JF, Simons MY, Russell NS, Daemen MJ, Stewart FA. NO-donating aspirin and aspirin partially inhibit age-related atherosclerosis but not radiation-induced atherosclerosis in ApoE null mice. PLoS One. 2010;5:e12874. doi: 10.1371/journal.pone.0012874CrossrefPubMedGoogle Scholar116.Patel DA, Kochanski J, Suen AW, Fajardo LF, Hancock SL, Knox SJ. Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation. Cancer. 2006;106:718–725. doi: 10.1002/cncr.21636CrossrefPubMedGoogle Scholar117.Brosius FC, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med. 1981;70:519–530. doi: 10.1016/0002-9343(81)90574-xCrossrefPubMedGoogle Scholar118.Virmani R, Farb A, Carter AJ, Jones RM. Pathology of radiation-induced coronary artery disease in human and pig. Cardiovasc Radiat Med. 1999;1:98–101. doi: 10.1016/s1522-1865(98)00010-9CrossrefPubMedGoogle Scholar119.Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol. 1996;27:766–773. doi: 10.1016/s0046-8177(96)90447-5CrossrefPubMedGoogle Scholar120.Christersdottir T, Pirault J, Gistera A, Bergman O, Gallina AL, Baumgartner R, Lundberg AM, Eriksson P, Yan ZQ, Paulsson-Berne G, et al. Prevention of radiotherapy-induced arterial inflammation by interleukin-1 blockade. Eur Heart J. 2019;40:2495–2503. doi: 10.1093/eurheartj/ehz206CrossrefPubMedGoogle Scholar121.Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, Soff G, Parameswaran R, Hassoun H. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29:3466–3473. doi: 10.1200/JCO.2011.35.5669CrossrefPubMedGoogle Scholar122.Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277–2285. doi: 10.1001/jama.2008.656CrossrefPubMedGoogle Scholar123.Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, Beckman JA, Harrison DG, Moslehi J. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018;71:e1–e8. doi: 10.1161/HYPERTENSIONAHA.117.10271CrossrefPubMedGoogle Scholar124.Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–1239. doi: 10.1093/jnci/djm086CrossrefPubMedGoogle Scholar125.Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018;12:409–425. doi: 10.1016/j.jash.2018.03.008CrossrefPubMedGoogle Scholar126.Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49:287–297. doi: 10.3109/02841860903524396CrossrefPubMedGoogle Scholar127.Chen XL, Lei YH, Liu CF, Yang QF, Zuo PY, Liu CY, Chen CZ, Liu YW. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One. 2013;8:e66721. doi: 10.1371/journal.pone.0066721CrossrefPubMedGoogle Scholar128.Chitkara A, Kaur N, Desai A, Mehta D, Anamika F, Sarkar S, Gowda N, Sethi P, Thawani R, Chen EY. Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: a systematic review and meta-analysis. Cancer Med. 2023;12:21579–21591. doi: 10.1002/cam4.6662CrossrefPubMedGoogle Scholar129.Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients. J Am Heart Assoc. 2017;6:e006278. doi: 10.1161/JAHA.117.006278CrossrefPubMedGoogle Scholar130.Qi WX, Shen Z, Tang LN, Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit Rev Oncol Hematol. 2014;92:71–82. doi: 10.1016/j.critrevonc.2014.04.004CrossrefPubMedGoogle Scholar131.Totzeck M, Mincu RI, Mrotzek S, Schadendorf D, Rassaf T. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol. 2018;25:482–494. doi: 10.1177/2047487318755193CrossrefPubMedGoogle Scholar132.Liu B, Ding F, Zhang D, Wei GH. Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis. Cancer Chemother Pharmacol. 2017;80:487–495. doi: 10.1007/s00280-017-3386-6CrossrefPubMedGoogle Scholar133.Saez Perdomo MN, Stuckey R, González-Pérez E, Sánchez-Sosa S, Estupiñan-Cabrera P, Lakhwani Lakhwani S, González San Miguel JD, Hernanz Soler N, Gordillo M, González Brito G, et al. The cardiovascular event risk associated with tyrosine kinase inhibitors and the lipid profile in patients with chronic myeloid leukemia. Hematol Rep. 2024;16:140–150. doi: 10.3390/hematolrep16010015CrossrefPubMedGoogle Scholar134.Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol. 2013;90:531–532. doi: 10.1111/ejh.12096CrossrefPubMedGoogle Scholar135.Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393–404. doi: 10.1182/blood-2016-09-739086CrossrefPubMedGoogle Scholar136.Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Sgherza N, Bonifacio M, et al. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematol Oncol. 2019;37:296–302. doi: 10.1002/hon.2606CrossrefPubMedGoogle Scholar137.Nichols ED, Jabbour E, Jammal N, Chew S, Bryan J, Issa G, Garcia-Manero G, Sasaki K, DiPippo A, Kantarjian H. Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. Am J Hematol. 2022;97:E350–E352. doi: 10.1002/ajh.26645CrossrefPubMedGoogle Scholar138.Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Morris MJ, Scardino PT, Eastham JA, Elkin EB. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer. 2012;118:3397–3406. doi: 10.1002/cncr.26623CrossrefPubMedGoogle Scholar139.Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, Ingelsson E, Lambe M, Stattin P, Holmberg L. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 2010;11:450–458. doi: 10.1016/S1470-2045(10)70038-3CrossrefPubMedGoogle Scholar140.Gupta D, Lee Chuy K, Yang JC, Bates M, Lombardo M, Steingart RM. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract. 2018;14:580–587. doi: 10.1200/JOP.18.00178CrossrefPubMedGoogle Scholar141.Aziz MK, Molony D, Monlezun D, Holder T, Brunckhorst O, Higgason N, Roland J, Magill R, Fatakdawala M, Iacobucci A, et al; European Association of Urology Prostate Cancer Guidelines Panel. Prostate cancer therapy cardiotoxicity map (PROXMAP) for advanced disease states: a systematic review and network meta-analysis with Bayesian modeling of treatment histories. Eur Urol. 2025;87:15–26. doi: 10.1016/j.eururo.2024.08.031CrossrefPubMedGoogle Scholar142.Hernandez RK, Sørensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer. 2009;115:4442–4449. doi: 10.1002/cncr.24508CrossrefPubMedGoogle Scholar143.Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab. 1995;80:3191–3195. doi: 10.1210/jcem.80.11.7593425CrossrefPubMedGoogle Scholar144.Khosrow-Khavar F, Filion KB, Al-Qurashi S, Torabi N, Bouganim N, Suissa S, Azoulay L. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017;28:487–496. doi: 10.1093/annonc/mdw673CrossrefPubMedGoogle Scholar145.Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G, Moslehi J. Cardiovascular complications of novel multiple myeloma treatments. Circulation. 2016;133:908–912. doi: 10.1161/CIRCULATIONAHA.115.018351CrossrefPubMedGoogle Scholar146.Ma Z, Sun X, Zhang Y, Li H, Sun D, An Z, Zhang Y. Risk of thromboembolic events in cancer patients treated with immune checkpoint inhibitors: a meta-analysis of randomized controlled trials. Thromb Haemost. 2022;122:1757–1766. doi: 10.1055/s-0042-1749185CrossrefPubMedGoogle Scholar147.Khorana AA, Palaia J, Rosenblatt L, Pisupati R, Huang N, Nguyen C, Barron J, Gallagher K, Bond TC. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer. J ImmunoTher Cancer. 2023;11:e006072. doi: 10.1136/jitc-2022-006072CrossrefPubMedGoogle Scholar148.Overvad TF, Skjøth F, Piazza G, Noble S, Ording AG, Larsen TB, Nielsen PB. The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: a Danish cohort study. J Thromb Haemost. 2022;20:2921–2929. doi: 10.1111/jth.15883CrossrefPubMedGoogle Scholar149.Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20:1370–1385. doi: 10.1016/S1470-2045(19)30413-9CrossrefPubMedGoogle Scholar150.Bindal P, Patell R, Chiasakul T, Lauw MN, Ko A, Wang TF, Zwicker JI. A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost. 2024;22:2071–2080. doi: 10.1016/j.jtha.2024.03.021CrossrefPubMedGoogle Scholar151.Tanimura K, Otake H, Kawamori H, Toba T, Nagasawa A, Nakano S, Takahashi Y, Fukuyama Y, Kozuki A, Shite J, et al. Morphological plaque characteristics and clinical outcomes in patients with acute coronary syndrome and a cancer history. J Am Heart Assoc. 2021;10:e020243. doi: 10.1161/JAHA.120.020243CrossrefPubMedGoogle Scholar152.Wang C, Tian X, Feng X, Demuyakor A, Hu S, Wang Y, Li L, Cui L, Dong F, Dai J, et al. Pancoronary plaque characteristics and clinical outcomes in acute coronary syndrome patients with cancer history. Atherosclerosis. 2023;378:117118. doi: 10.1016/j.atherosclerosis.2023.03.023CrossrefPubMedGoogle Scholar153.Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114:1852–1866. doi: 10.1161/CIRCRESAHA.114.302721CrossrefPubMedGoogle Scholar154.McElroy M, Kim Y, Niccoli G, Vergallo R, Langford-Smith A, Crea F, Gijsen F, Johnson T, Keshmiri A, White SJ. Identification of the haemodynamic environment permissive for plaque erosion. Sci Rep. 2021;11:7253. doi: 10.1038/s41598-021-86501-xCrossrefPubMedGoogle Scholar155.Meteva D, Vinci R, Seppelt C, Abdelwahed YS, Pedicino D, Nelles G, Skurk C, Haghikia A, Rauch-Kröhnert U, Gerhardt T, et al. Toll-like receptor 2, hyaluronan, and neutrophils play a key role in plaque erosion: the OPTICO-ACS study. Eur Heart J. 2023;44:3892–3907. doi: 10.1093/eurheartj/ehad379CrossrefPubMedGoogle Scholar156.Yoo J, Kwon I, Kim S, Kim HM, Kim YD, Nam HS, Heo JH. Coagulation factor expression and composition of arterial thrombi in cancer-associated stroke. Stroke. 2023;54:2981–2989. doi: 10.1161/STROKEAHA.123.044910CrossrefPubMedGoogle Scholar157.Bang OY, Chung JW, Cho YH, Oh MJ, Seo WK, Kim GM, Ahn MJ. Circulating DNAs, a marker of neutrophil extracellular traposis and cancer-related stroke: the OASIS-cancer study. Stroke. 2019;50:2944–2947. doi: 10.1161/STROKEAHA.119.026373CrossrefPubMedGoogle Scholar158.Demers M, Wong SL, Martinod K, Gallant M, Cabral JE, Wang Y, Wagner DD. Priming of neutrophils toward NETosis promotes tumor growth. Oncoimmunology. 2016;5:e1134073. doi: 10.1080/2162402X.2015.1134073CrossrefPubMedGoogle Scholar159.Galgano L, Guidetti GF, Torti M, Canobbio I. The controversial role of LPS in platelet activation in vitro. Int J Mol Sci. 2022;23:10900. doi: 10.3390/ijms231810900CrossrefPubMedGoogle Scholar160.Su X, Brassard A, Bartolomucci A, Dhoparee-Doomah I, Qiu Q, Tsering T, Rohanizadeh R, Koufos O, Giannias B, Bourdeau F, et al. Tumour extracellular vesicles induce neutrophil extracellular traps to promote lymph node metastasis. J Extracell Vesicles. 2023;12:e12341. doi: 10.1002/jev2.12341CrossrefPubMedGoogle Scholar161.Bang OY, Chung JW, Lee MJ, Kim SJ, Cho YH, Kim GM, Chung CS, Lee KH, Ahn MJ, Moon GJ. Cancer cell-derived extracellular vesicles are associated with coagulopathy causing ischemic stroke via tissue factor-independent way: the OASIS-CANCER study. PLoS One. 2016;11:e0159170. doi: 10.1371/journal.pone.0159170CrossrefPubMedGoogle Scholar162.Leal AC, Mizurini DM, Gomes T, Rochael NC, Saraiva EM, Dias MS, Werneck CC, Sielski MS, Vicente CP, Monteiro RQ. Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancer-associated thrombosis. Sci Rep. 2017;7:6438. doi: 10.1038/s41598-017-06893-7CrossrefPubMedGoogle Scholar163.Dudiki T, Veleeparambil M, Zhevlakova I, Biswas S, Klein EA, Ford P, Podrez EA, Byzova TV. Mechanism of tumor-platelet communications in cancer. Circ Res. 2023;132:1447–1461. doi: 10.1161/CIRCRESAHA.122.321861CrossrefPubMedGoogle Scholar164.Shindo K, Aishima S, Ohuchida K, Fujiwara K, Fujino M, Mizuuchi Y, Hattori M, Mizumoto K, Tanaka M, Oda Y. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol Cancer. 2013;12:168. doi: 10.1186/1476-4598-12-168CrossrefPubMedGoogle Scholar165.Woei-A-Jin FJ, Tesselaar ME, Garcia Rodriguez P, Romijn FP, Bertina RM, Osanto S. Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis? Br J Cancer. 2016;115:332–338. doi: 10.1038/bjc.2016.170CrossrefPubMedGoogle Scholar166.Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018;10:380. doi: 10.3390/cancers10100380CrossrefPubMedGoogle Scholar167.Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol. 2018;72:89–93. doi: 10.1016/j.jjcc.2018.02.011CrossrefPubMedGoogle Scholar168.Geddings JE, Hisada Y, Boulaftali Y, Getz TM, Whelihan M, Fuentes R, Dee R, Cooley BC, Key NS, Wolberg AS, et al. Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost. 2016;14:153–166. doi: 10.1111/jth.13181CrossrefPubMedGoogle Scholar169.Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, Baker CH, Francis JL. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost. 2008;6:1517–1524. doi: 10.1111/j.1538-7836.2008.02987.xCrossrefPubMedGoogle Scholar170.Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, Hostetter G, Harvey J, Taubman MB. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13:2870–2875. doi: 10.1158/1078-0432.CCR-06-2351CrossrefPubMedGoogle Scholar171.Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol. 2009;27:4834–4838. doi: 10.1200/JCO.2009.22.6324CrossrefPubMedGoogle Scholar172.Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105:1734–1741. doi: 10.1182/blood-2004-05-2042CrossrefPubMedGoogle Scholar173.Regina S, Valentin JB, Lachot S, Lemarié E, Rollin J, Gruel Y. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem. 2009;55:1834–1842. doi: 10.1373/clinchem.2009.123695CrossrefPubMedGoogle Scholar174.Falanga A, Marchetti M, Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res. 2015;135(Suppl 1):S8–S11. doi: 10.1016/S0049-3848(15)50432-5CrossrefPubMedGoogle Scholar175.Nasser NJ, Fox J, Agbarya A. Potential mechanisms of cancer-related hypercoagulability. Cancers (Basel). 2020;12:566. doi: 10.3390/cancers12030566CrossrefPubMedGoogle Scholar176.Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015;3:83–92. doi: 10.2147/HP.S93413CrossrefPubMedGoogle Scholar177.Di Virgilio F, Adinolfi E. Extracellular purines, purinergic receptors and tumor growth. Oncogene. 2017;36:293–303. doi: 10.1038/onc.2016.206CrossrefPubMedGoogle Scholar178.Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70:926–938. doi: 10.1016/j.jacc.2017.06.047CrossrefPubMedGoogle Scholar179.Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, Panageas KS, DeAngelis LM. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2019;133:781–789. doi: 10.1182/blood-2018-06-860874CrossrefPubMedGoogle Scholar180.Wang J, Kim YD, Kim CH. Incidence and risk of various types of arterial thromboembolism in patients with cancer. Mayo Clin Proc. 2021;96:592–600. doi: 10.1016/j.mayocp.2020.05.045CrossrefPubMedGoogle Scholar181.Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, van den Berg MP, Burgerhof JG, Hoekstra HJ, Sluiter WJ, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 2004;40:701–706. doi: 10.1016/j.ejca.2003.12.012CrossrefPubMedGoogle Scholar182.Kim AS, Khorana AA, McCrae KR. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res. 2020;225:33–53. doi: 10.1016/j.trsl.2020.06.012CrossrefPubMedGoogle Scholar183.Chen N, Ren M, Li R, Deng X, Li Y, Yan K, Xiao L, Yang Y, Wang L, Luo M, et al. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma. Mol Cancer. 2015;14:140. doi: 10.1186/s12943-015-0418-xCrossrefPubMedGoogle Scholar184.Pouwer MG, Pieterman EJ, Verschuren L, Caspers MPM, Kluft C, Garcia RA, Aman J, Jukema JW, Princen HMG. The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model. Front Cardiovasc Med. 2018;5:55. doi: 10.3389/fcvm.2018.00055CrossrefPubMedGoogle Scholar185.Merkulova A, Mitchell SC, Stavrou EX, Forbes GL, Schmaier AH. Ponatinib treatment promotes arterial thrombosis and hyperactive platelets. Blood Adv. 2019;3:2312–2316. doi: 10.1182/bloodadvances.2019000034CrossrefPubMedGoogle Scholar186.Aguila S, Cuenca EJ, Lys MJ, Garcia-Hernandez C, Fernández MJ, Noya M, García Gutiérrez V, Palomera L, Senín A, Perez Lopez R, et al. Thrombogenesis mechanisms of high doses of ponatinib in patients with Chronic Myeloid Leukemia (CML) compared to tyrosine kinase inhibitors. Blood. 2022;140:6730–6732. doi: 10.1182/blood-2022-163070CrossrefGoogle Scholar187.Telerman A, Granot G, Leibovitch C, Yarchovsky-Dolberg O, Shacham-Abulafia A, Partouche S, Yeshurun M, Ellis MH, Raanani P, Wolach O. Neutrophil extracellular traps are increased in chronic myeloid leukemia and are differentially affected by tyrosine kinase inhibitors. Cancers (Basel). 2021;14:119. doi: 10.3390/cancers14010119CrossrefPubMedGoogle Scholar188.Stepanian A, Travers RJ, Tesfu A, Wolter NL, Man JJ, Lu Q, Shamsuzzaman S, Deaton RA, Owens GK, Chen CS, et al. Ponatinib, but not the new Abl-kinase inhibitor asciminib, activates platelets, leukocytes, and endothelial cell TNF signaling to induce atherosclerotic plaque inflammation, myocardial infarction, and stroke. Circulation. 2025;152:765–783. doi: 10.1161/CIRCULATIONAHA.125.073610CrossrefPubMedGoogle Scholar189.Rühl H, Schröder L, Müller J, Fimmers R, Sukhitashvili S, Welz J, Kuhn WC, Oldenburg J, Rudlowski C, Pötzsch B. Tamoxifen induces resistance to activated protein C. Thromb Res. 2014;133:886–891. doi: 10.1016/j.thromres.2014.02.004CrossrefPubMedGoogle Scholar190.Ceschi A, Noseda R, Palin K, Verhamme K. Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database. Front Pharmacol. 2020;11:557. doi: 10.3389/fphar.2020.00557CrossrefPubMedGoogle Scholar191.Cánovas MS, Garay DF, Moran LO, Pérez JR, Rubio CMG, de Mena ML, Portero BO, Castro JB, Lage Y, Lavin DC, et al. Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group. Clin Transl Oncol. 2022;24:2010–2020. doi: 10.1007/s12094-022-02860-5CrossrefPubMedGoogle Scholar192.Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol. 2008;103:398–406. doi: 10.1007/s00395-008-0733-0CrossrefPubMedGoogle Scholar193.Youssef A, Kasso N, Torloni AS, Stanek M, Dragovich T, Gimbel M, Mahmoud F. Thrombotic thrombocytopenic purpura due to checkpoint inhibitors. Case Rep Hematol. 2018;2018:2464619. doi: 10.1155/2018/2464619CrossrefPubMedGoogle Scholar194.Fonkalsrud EW, Sanchez M, Zerubavel R, Mahoney A. Serial changes in arterial structure following radiation therapy. Surg Gynecol Obstet. 1977;145:395–400.PubMedGoogle Scholar195.Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, Dimmeler S, Zeiher AM. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111:2981–2987. doi: 10.1161/CIRCULATIONAHA.104.504340CrossrefPubMedGoogle Scholar196.Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1–E7. doi: 10.1161/hh1301.093953CrossrefPubMedGoogle Scholar197.Wong M, Grossman J, Hahn BH, La Cava A. Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin Immunol. 2008;129:3–9. doi: 10.1016/j.clim.2008.07.001CrossrefPubMedGoogle Scholar198.Kulkarni U, Nayak V, Prabhu MM, Rao R. Tamoxifen-induced vasculitis. J Oncol Pharm Pract. 2020;26:735–737. doi: 10.1177/1078155219862342CrossrefPubMedGoogle Scholar199.Fukui M, Shiraishi K, Yoshida S, Yatsuzuka K, Matsumoto T, Sayama K. Olaparib-induced cutaneous vasculitis in a patient with recurrent ovarian cancer. Eur J Dermatol. 2022;32:655–656. doi: 10.1684/ejd.2022.4343CrossrefPubMedGoogle Scholar200.Bock VL, Friedlander M, Waring D, Kossard S, Wood GK. Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. Australas J Dermatol. 2014;55:282–285. doi: 10.1111/ajd.12110CrossrefPubMedGoogle Scholar201.Muzzana M, Pedrazzoli P, Lasagna A. G-CSF and G-CSF-related vasculitis: a systematic review of the literature and intriguing future research perspectives. Future Oncol. 2021;17:4619–4634. doi: 10.2217/fon-2021-0701CrossrefPubMedGoogle Scholar202.Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol. 2018;14:569–579. doi: 10.1038/s41584-018-0074-9CrossrefPubMedGoogle Scholar203.Lee CM, Wang M, Rajkumar A, Calabrese C, Calabrese L. A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: unraveling the complexities at the intersection of immunology and vascular pathology. Semin Arthritis Rheum. 2024;66:152440. doi: 10.1016/j.semarthrit.2024.152440CrossrefPubMedGoogle Scholar204.Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, Judge A, Hutchings A, Merkel PA, Luqmani RA, et al; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Arthritis Rheumatol. 2022;74:400–406. doi: 10.1002/art.41983CrossrefPubMedGoogle Scholar205.Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579–1589. doi: 10.1016/S1470-2045(18)30608-9CrossrefPubMedGoogle Scholar206.Zhang H, Watanabe R, Berry GJ, Vaglio A, Liao YJ, Warrington KJ, Goronzy JJ, Weyand CM. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci USA. 2017;114:E970–E979. doi: 10.1073/pnas.1616848114CrossrefPubMedGoogle Scholar207.Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018;37:2579–2584. doi: 10.1007/s10067-018-4177-0CrossrefPubMedGoogle Scholar208.Aya F, Ruiz-Esquide V, Viladot M, Font C, Prieto-González S, Prat A, Arance A. Vasculitic neuropathy induced by pembrolizumab. Ann Oncol. 2017;28:433–434. doi: 10.1093/annonc/mdw613CrossrefPubMedGoogle Scholar209.Cheng C, Nguyen MN, Nayernama A, Jones SC, Brave M, Agrawal S, Amiri-Kordestani L, Woronow D. Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: a review of cases reported to the FDA Adverse Event Reporting System and published in the literature. Vasc Med. 2021;26:526–534. doi: 10.1177/1358863X211006470CrossrefPubMedGoogle Scholar210.Guyon J, Gouverneur A, Maumus-Robert S, Bérard X, Pariente A, Bikfalvi A, Noize P. Association between antiangiogenic drugs used for cancer treatment and artery dissections or aneurysms. JAMA Oncol. 2021;7:775–778. doi: 10.1001/jamaoncol.2021.0210CrossrefPubMedGoogle Scholar211.Wang S, Chen M, Zhang X, Zhang L, Jia M, Shen Z, Wang J, Zhao B, Gong Y, Gong J. Aneurysm and artery dissection following the use of vascular endothelial growth factor inhibitor: a real-world analysis using a spontaneous reporting system. J Am Heart Assoc. 2021;10:e020844. doi: 10.1161/JAHA.121.020844CrossrefPubMedGoogle Scholar212.Oshima Y, Tanimoto T, Yuji K, Tojo A. Association between aortic dissection and systemic exposure of vascular endothelial growth factor pathway inhibitors in the Japanese adverse drug event report database. Circulation. 2017;135:815–817. doi: 10.1161/CIRCULATIONAHA.116.025144CrossrefPubMedGoogle Scholar213.Kang S, Yeon B, Kim MS, Yoo M, Kim B, Yu YM. Aneurysm and artery dissection after oral VEGFR-TKI use in adults with cancer. JAMA Netw Open. 2023;6:e2345977. doi: 10.1001/jamanetworkopen.2023.45977CrossrefPubMedGoogle Scholar214.Wu CW, Huang HY, Lin SY, Wang CC, Huang CF, Wu IH. Vascular endothelial growth factor inhibitors and the risk of aortic aneurysm and aortic dissection. JAMA Netw Open. 2024;7:e240940. doi: 10.1001/jamanetworkopen.2024.0940CrossrefPubMedGoogle Scholar215.Balanescu DV, Bloomingdale R, Donisan T, Yang EH, Parwani P, Iliescu C, Herrmann J, Hanson I. Mechanisms of myocardial ischemia in cancer patients: a state-of-the-art review of obstructive versus non-obstructive causes. Rev Cardiovasc Med. 2022;23:227. doi: 10.31083/j.rcm2307227CrossrefPubMedGoogle Scholar216.Panday P, Hausvater A, Pleasure M, Smilowitz NR, Reynolds HR. Cancer and myocardial infarction in women. Am J Cardiol. 2023;194:27–33. doi: 10.1016/j.amjcard.2023.02.007CrossrefPubMedGoogle Scholar217.Peng X, Zhu Z, Tang J, Zhou S. Spontaneous coronary artery dissection accompanied with antiphospholipid syndrome and leukemia. Int Heart J. 2018;59:891–894. doi: 10.1536/ihj.17-462CrossrefPubMedGoogle Scholar218.Kavyani R, Salari S, Norozi Z, Hosseini S, Abdi S, Rai A, Maleki M. Left main and three vessels spontaneous coronary artery dissection as an incidental finding in young man with history of Hodgkin’s lymphoma-a case report. BMC Cardiovasc Disord. 2024;24:14. doi: 10.1186/s12872-023-03609-wCrossrefPubMedGoogle Scholar219.Karabay CY, Biteker M, Zehir R, Bezgin T, Tanboga H, Can MM, Güler A, Duran NE, Ozkan M. Multiple spontaneous coronary artery dissection associated with Trousseau’s syndrome. Cardiol J. 2010;17:625–627.PubMedGoogle Scholar220.Hart K, Patel S, Kovoor J. Spontaneous coronary artery dissection associated with anal cancer management with fluorouracil and radiotherapy. Cureus. 2019;11:e4979. doi: 10.7759/cureus.4979CrossrefPubMedGoogle Scholar221.Saffar H, Abdan L, Abdan Z, Hekmat H, Amirzadegan A, Omidi N. Spontaneous coronary artery dissection in the context of tamoxifen; Is there any correlation? Clin Case Rep. 2024;12:e9140. doi: 10.1002/ccr3.9140CrossrefPubMedGoogle Scholar222.Gilyarov MY, Rozhkov A, Selyutskii S. Spontaneous dissection of coronary arteries in patients receiving combined antitumor therapy with cisplatin and capecitabine. Emerg. Cardiol. 2014;2:28–34.Google Scholar223.Mir MA, Patnaik MM, Herrmann J. Spontaneous coronary artery dissection during hematopoietic stem cell infusion. Blood. 2013;122:3388–3389. doi: 10.1182/blood-2013-09-528760CrossrefPubMedGoogle Scholar224.Donisan T, Herrmann J, Gulati R, Alkhouli MA, Hampel P, Borlaug B. Multivessel spontaneous coronary artery dissections associated with acalabrutinib. J Am Coll Cardiol. 2023;81:3331–3331. doi: 10.1016/s0735-1097(23)03775-0CrossrefGoogle Scholar225.Xu B, Iida Y, Glover KJ, Ge Y, Wang Y, Xuan H, Hu X, Tanaka H, Wang W, Fujimura N, et al. Inhibition of VEGF (vascular endothelial growth factor)-A or its receptor activity suppresses experimental aneurysm progression in the aortic elastase infusion model. Arterioscler Thromb Vasc Biol. 2019;39:1652–1666. doi: 10.1161/ATVBAHA.119.312497CrossrefPubMedGoogle Scholar226.Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Lond). 2016;16:481–485. doi: 10.7861/clinmedicine.16-5-481CrossrefPubMedGoogle Scholar227.Dai S, Zhong Y, Cui H, Zhao J, Li S. Aortic dissection induced by vascular endothelial growth factor inhibitors. Front Pharmacol. 2023;14:1189910. doi: 10.3389/fphar.2023.1189910CrossrefPubMedGoogle Scholar228.Hayes SN, Tweet MS, Adlam D, Kim ESH, Gulati R, Price JE, Rose CH. Spontaneous coronary artery dissection: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76:961–984. doi: 10.1016/j.jacc.2020.05.084CrossrefPubMedGoogle Scholar229.Cortes J, Saura C, Atzori F. Risk of venous thromboembolism with bevacizumab in cancer patients. JAMA. 2009;301:1434–5, author reply 1435. doi: 10.1001/jama.2009.440CrossrefPubMedGoogle Scholar230.Minor DR. Risk of venous thromboembolism with bevacizumab in cancer patients. JAMA. 2009;301:1434. doi: 10.1001/jama.2009.439CrossrefPubMedGoogle Scholar231.Minor DR. Risk of arterial thrombosis not increased by sorafenib or sunitinib. J Clin Oncol. 2010;28:e619; author reply e620. doi: 10.1200/JCO.2010.31.0219CrossrefPubMedGoogle ScholarShow all references
eLetterseLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article
Information & AuthorsInformationAuthorsInformationPublished In
Arteriosclerosis, Thrombosis, and Vascular BiologyVolume 46 • Number 2 • February 2026Page: e319867PubMed: 41376595Copyright© 2025 American Heart Association, Inc.VersionsYou are viewing the most recent version of this article.11 December 2025: Ahead of PrintHistoryPublished online: 11 December 2025Published in print: February 2026PermissionsRequest permissions for this article.Request permissionsKeywordsaneurysmfluorouracilimmune checkpoint inhibitorsneoplasmsvasculitisSubjectsVascular DiseaseAuthorsAffiliationsExpand AllTeodora DonisanDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.D., D.V.B., A.L., J.H.).View all articles by this authorDinu V. BalanescuDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.D., D.V.B., A.L., J.H.).View all articles by this authorJun-ichi Abe https://orcid.org/0000-0001-7439-7774Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston (J.-i.A., C.A.I.).View all articles by this authorAmir Lerman https://orcid.org/0000-0002-9446-5313Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.D., D.V.B., A.L., J.H.).View all articles by this authorCezar A. Iliescu https://orcid.org/0000-0002-8817-4579Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston (J.-i.A., C.A.I.).View all articles by this authorJoerg Herrmann https://orcid.org/0000-0001-6675-4559 herrmann.joerg@mayo.eduDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.D., D.V.B., A.L., J.H.).View all articles by this authorNotesATVB in Focus: Cardio-Oncology and Vascular DiseasesSeries Editor: Jun-ichi AbeFor Sources of Funding and Disclosures, see page 342.Correspondence to: Joerg Herrmann, MD, Department of Cardiovascular Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905. Email herrmann.joerg@mayo.eduDisclosuresNone.Sources of FundingJ.-i. Abe received funding from the National Institutes of Health (NIH; HL-149303 and AI-156921). J. Herrmann received research funding from the National Cancer Institute (CA233610), the US Department of Defense (CA240941, Award Number HT9425-25-1-0309), and the Miami Heart Research Foundation.Metrics & CitationsMetricsCitationsMetrics
Article MetricsView all metricsDownloadsCitationsNo data available.020406080100120Dec 2025Jan 20262140TotalFirst 90 DaysTotal number of
downloads
See more details
On 1 Facebook pages
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Please select your download format:
RIS (ProCite, Reference Manager)
EndNote
BibTex
Medlars
RefWorks
Direct Import
FiguresOpen all in viewerGo to FigureOpen in ViewerTablesMediaShareShareShare article linkhttps://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.125.319867Copy LinkCopied!Copying failed.ShareFacebookLinkedInX (formerly Twitter)emailWeChatBlueskyGet AccessGet Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login
Institutional Login
Email
Password
Forgot your password? Reset it
here
Keep me logged in
Login
Don’t have an account? Register
here
Save for later
Item saved, go to cart
Purchase Options
Purchase this article to access the full text.
Purchase access to this article for 24 hours
Vascular Toxicities of Cancer Therapies: 2025 Update
Arteriosclerosis, Thrombosis, and Vascular Biology
Vol. 46
No. 2
pp. e323501-
USD
$35.00
Add to Cart
Checkout
Purchase access to this journal for 24 hours
Arteriosclerosis, Thrombosis, and Vascular Biology
Vol. 46
No. 2
pp. e323501-
USD
$40.00
Add to Cart
Checkout
Restore your content access
Enter your email address to restore your content access:
Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.
ReferencesReferencesReferences1.Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol. 2020;17:503–522. doi: 10.1038/s41569-020-0347-2CrossrefPubMedGoogle Scholar2.Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N. Cancer therapy-associated thrombosis. Arterioscler Thromb Vasc Biol. 2021;41:1291–1305. doi: 10.1161/ATVBAHA.120.314378CrossrefPubMedGoogle Scholar3.Südhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, Schmiegel W. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15:661–664. doi: 10.1093/annonc/mdh150CrossrefPubMedGoogle Scholar4.Hammond ST, Baumfalk DR, Parr SK, Butenas ALE, Scheuermann BC, Turpin VG, Behnke BJ, Hashmi MH, Ade CJ. Impaired microvascular reactivity in patients treated with 5-fluorouracil chemotherapy regimens: potential role of endothelial dysfunction. Int J Cardiol Heart Vasc. 2023;49:101300. doi: 10.1016/j.ijcha.2023.101300CrossrefPubMedGoogle Scholar5.Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974–984. doi: 10.1016/j.ctrv.2013.03.005CrossrefPubMedGoogle Scholar6.Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134:75–82. doi: 10.1007/s00432-007-0250-9CrossrefPubMedGoogle Scholar7.Zafar A, Drobni ZD, Lei M, Gongora CA, Quinaglia T, Lou UY, Mosarla R, Murphy SP, Jones-O’Connor M, Mahmood A, et al. The efficacy and safety of cardio-protective therapy in patients with 5-FU (fluorouracil)-associated coronary vasospasm. PLoS One. 2022;17:e0265767. doi: 10.1371/journal.pone.0265767CrossrefPubMedGoogle Scholar8.Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer. 2005;41:1542–1546. doi: 10.1016/j.ejca.2005.03.027CrossrefPubMedGoogle Scholar9.Yung LT, McCrea WA. Capecitabine induced acute coronary syndrome. BMJ Case Rep. 2009;2009:bcr09.2008.0964. doi: 10.1136/bcr.09.2008.0964CrossrefPubMedGoogle Scholar10.Kobayashi N, Hata N, Yokoyama S, Shinada T, Shirakabe A, Mizuno K. A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. J Nippon Med Sch. 2009;76:27–33. doi: 10.1272/jnms.76.27CrossrefPubMedGoogle Scholar11.Thijs AMJ, van Herpen CML, Sweep FCGJ, Geurts-Moespot A, Smits P, van der Graaf WTA, Rongen GA. Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans. Hypertension. 2013;61:1060–1065. doi: 10.1161/HYPERTENSIONAHA.111.00841CrossrefPubMedGoogle Scholar12.Chintalgattu V, Rees ML, Culver JC, Goel A, Jiffar T, Zhang J, Dunner K, Pati S, Bankson JA, Pasqualini R, et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 2013;5:187ra169. doi: 10.1126/scitranslmed.3005066CrossrefGoogle Scholar13.Sen F, Yildiz I, Basaran M, Ekenel M, Oz F, Kilic L, Toz B, Gurdal A, Camlica H, Bavbek S, et al. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib. J BUON. 2013;18:775–781.PubMedGoogle Scholar14.Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz. 2011;36:348–351. doi: 10.1007/s00059-011-3444-5CrossrefPubMedGoogle Scholar15.Kabir R, Vasquez N, Keshvani N, Vongpatanasin W. A case of chemotherapy-induced coronary vasospasm in a patient with colorectal cancer. J Cardiol Cases. 2020;22:117–120. doi: 10.1016/j.jccase.2020.05.014CrossrefPubMedGoogle Scholar16.Lim DH, Yoon JH, Jun DW, Lee OY, Yoon BC, Lee HR, Kim KS, Choi HS. Recurrent coronary artery vasospasm in a patient with hepatocellular carcinoma treated with sorafenib: a case report and literature review. J Liver Cancer. 2020;20:67–71. doi: 10.17998/jlc.20.1.67CrossrefPubMedGoogle Scholar17.Arima Y, Oshima S, Noda K, Fukushima H, Taniguchi I, Nakamura S, Shono M, Ogawa H. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol. 2009;54:512–515. doi: 10.1016/j.jjcc.2009.03.009CrossrefPubMedGoogle Scholar18.Hansen SW, Olsen N, Rossing N, Rørth M. Vascular toxicity and the mechanism underlying Raynaud’s phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Ann Oncol. 1990;1:289–292. doi: 10.1093/oxfordjournals.annonc.a057750CrossrefPubMedGoogle Scholar19.Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993;53:3028–3033.PubMedGoogle Scholar20.Otsu K, Tajiri K, Sakai S, Ieda M. Vasospastic angina following immune checkpoint blockade. Eur Heart J. 2020;41:1702. doi: 10.1093/eurheartj/ehz796CrossrefPubMedGoogle Scholar21.Kumamoto T, Kawano H, Kurobe M, Akashi R, Yonekura T, Ikeda S, Maemura K. Vasospastic angina: an immune-related adverse event. Intern Med. 2022;61:1983–1986. doi: 10.2169/internalmedicine.8540-21CrossrefPubMedGoogle Scholar22.Tao JJ, Roszkowska N, Majure DT, Mahmood SS. Coronary vasospasm during infusion of CD-19 directed chimeric antigen receptor T-cell therapy: a case report. Eur Heart J Case Rep. 2023;7:ytad342. doi: 10.1093/ehjcr/ytad342CrossrefPubMedGoogle Scholar23.Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, et al; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–2801. doi: 10.1093/eurheartj/ehw211CrossrefPubMedGoogle Scholar24.Beckman JA, Thakore A, Kalinowski BH, Harris JR, Creager MA. Radiation therapy impairs endothelium-dependent vasodilation in humans. J Am Coll Cardiol. 2001;37:761–765. doi: 10.1016/s0735-1097(00)01190-6CrossrefPubMedGoogle Scholar25.Kabir J, Lobo M, Zachary I. Staurosporine induces endothelial cell apoptosis via focal adhesion kinase dephosphorylation and focal adhesion disassembly independent of focal adhesion kinase proteolysis. Biochem J. 2002;367:145–155. doi: 10.1042/BJ20020665CrossrefPubMedGoogle Scholar26.Altieri P, Murialdo R, Barisione C, Lazzarini E, Garibaldi S, Fabbi P, Ruggeri C, Borile S, Carbone F, Armirotti A, et al. 5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1. Br J Pharmacol. 2017;174:3713–3726. doi: 10.1111/bph.13725CrossrefPubMedGoogle Scholar27.Schäfer A, Burkhardt M, Vollkommer T, Bauersachs J, Münzel T, Walter U, Smolenski A. Endothelium-dependent and -independent relaxation and VASP serines 157/239 phosphorylation by cyclic nucleotide-elevating vasodilators in rat aorta. Biochem Pharmacol. 2003;65:397–405. doi: 10.1016/s0006-2952(02)01523-xCrossrefPubMedGoogle Scholar28.Reiser J, Sever S, Faul C. Signal transduction in podocytes--spotlight on receptor tyrosine kinases. Nat Rev Nephrol. 2014;10:104–115. doi: 10.1038/nrneph.2013.274CrossrefPubMedGoogle Scholar29.Roskoski R. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007;356:323–328. doi: 10.1016/j.bbrc.2007.02.156CrossrefPubMedGoogle Scholar30.Barandier C, Ming XF, Rusconi S, Yang Z. PKC is required for activation of ROCK by RhoA in human endothelial cells. Biochem Biophys Res Commun. 2003;304:714–719. doi: 10.1016/s0006-291x(03)00668-5CrossrefPubMedGoogle Scholar31.Bárány K, Polyák E, Bárány M. Involvement of calponin and caldesmon in sustained contraction of arterial smooth muscle. Biochem Biophys Res Commun. 1992;187:847–852. doi: 10.1016/0006-291x(92)91274-tCrossrefPubMedGoogle Scholar32.Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14:7272–7283. doi: 10.1158/1078-0432.CCR-08-0652CrossrefPubMedGoogle Scholar33.Mongiardi MP, Radice G, Piras M, Stagni V, Pacioni S, Re A, Putti S, Ferrè F, Farsetti A, Pallini R, et al. Axitinib exposure triggers endothelial cells senescence through ROS accumulation and ATM activation. Oncogene. 2019;38:5413–5424. doi: 10.1038/s41388-019-0798-2CrossrefPubMedGoogle Scholar34.Winnik S, Lohmann C, Siciliani G, von Lukowicz T, Kuschnerus K, Kraenkel N, Brokopp CE, Enseleit F, Michels S, Ruschitzka F, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety. Int J Cardiol. 2013;168:2453–2461. doi: 10.1016/j.ijcard.2013.03.010CrossrefPubMedGoogle Scholar35.Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, Burstein HJ, Beckman JA. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension. 2011;58:85–92. doi: 10.1161/HYPERTENSIONAHA.110.168120CrossrefPubMedGoogle Scholar36.Alanazi WA, Alanazi AS, El-Nagar DM, Aljuraybah AM, Alsanea S, Alharbi M. Mechanism underlying triple VEGFR inhibitor tivozanib-induced hypertension in mice model. Pharmaceuticals (Basel). 2023;16:295. doi: 10.3390/ph16020295CrossrefPubMedGoogle Scholar37.Szczepaniak P, Siedlinski M, Hodorowicz-Zaniewska D, Nosalski R, Mikolajczyk TP, Dobosz AM, Dikalova A, Dikalov S, Streb J, Gara K, et al. Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism. J Clin Invest. 2022;132:e149117. doi: 10.1172/JCI149117CrossrefPubMedGoogle Scholar38.Sugimoto M, Nakayama M, Goto TM, Amano M, Komori K, Kaibuchi K. Rho-kinase phosphorylates eNOS at threonine 495 in endothelial cells. Biochem Biophys Res Commun. 2007;361:462–467. doi: 10.1016/j.bbrc.2007.07.030CrossrefPubMedGoogle Scholar39.Duquaine D, Hirsch GA, Chakrabarti A, Han Z, Kehrer C, Brook R, Joseph J, Schott A, Kalyanaraman B, Vasquez-Vivar J, et al. Rapid-onset endothelial dysfunction with Adriamycin: evidence for a dysfunctional nitric oxide synthase. Vasc Med. 2003;8:101–107. doi: 10.1191/1358863x03vm476oaCrossrefPubMedGoogle Scholar40.Cappetta D, De Angelis A, Sapio L, Prezioso L, Illiano M, Quaini F, Rossi F, Berrino L, Naviglio S, Urbanek K. Oxidative stress and cellular response to doxorubicin: a common factor in the complex milieu of anthracycline cardiotoxicity. Oxid Med Cell Longev. 2017;2017:1521020. doi: 10.1155/2017/1521020CrossrefPubMedGoogle Scholar41.Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. doi: 10.1016/j.biopha.2021.111708CrossrefPubMedGoogle Scholar42.Vásquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA, Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 1997;36:11293–11297. doi: 10.1021/bi971475eCrossrefPubMedGoogle Scholar43.Hader SN, Zinkevich N, Norwood Toro LE, Kriegel AJ, Kong A, Freed JK, Gutterman DD, Beyer AM. Detrimental effects of chemotherapy on human coronary microvascular function. Am J Physiol Heart Circ Physiol. 2019;317:H705–H710. doi: 10.1152/ajpheart.00370.2019CrossrefPubMedGoogle Scholar44.Galán-Arriola C, Vílchez-Tschischke JP, Lobo M, López GJ, de Molina-Iracheta A, Pérez-Martínez C, Villena-Gutiérrez R, Macías A, Díaz-Rengifo IA, Oliver E, et al. Coronary microcirculation damage in anthracycline cardiotoxicity. Cardiovasc Res. 2022;118:531–541. doi: 10.1093/cvr/cvab053CrossrefPubMedGoogle Scholar45.Menendez JC, Casanova D, Amado JA, Salas E, García-Unzueta MT, Fernandez F, de la Lastra LP, Berrazueta JR. Effects of radiation on endothelial function. Int J Radiat Oncol Biol Phys. 1998;41:905–913. doi: 10.1016/s0360-3016(98)00112-6CrossrefPubMedGoogle Scholar46.Baselet B, Sonveaux P, Baatout S, Aerts A. Pathological effects of ionizing radiation: endothelial activation and dysfunction. Cell Mol Life Sci. 2019;76:699–728. doi: 10.1007/s00018-018-2956-zCrossrefPubMedGoogle Scholar47.Jones P, Benghuzzi H, Tucci M, Richards L, Harrison G, Patel R. Pathophysiological changes associated with multiple exposure of ionizing radiation on MRC-5 cells in culture. Biomed Sci Instrum. 2007;43:254–259.PubMedGoogle Scholar48.Collins-Underwood JR, Zhao W, Sharpe JG, Robbins ME. NADPH oxidase mediates radiation-induced oxidative stress in rat brain microvascular endothelial cells. Free Radic Biol Med. 2008;45:929–938. doi: 10.1016/j.freeradbiomed.2008.06.024CrossrefPubMedGoogle Scholar49.Atochin DN, Wang A, Liu VW, Critchlow JD, Dantas AP, Looft-Wilson R, Murata T, Salomone S, Shin HK, Ayata C, et al. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J Clin Invest. 2007;117:1961–1967. doi: 10.1172/JCI29877CrossrefPubMedGoogle Scholar50.Hosoi Y, Yamamoto M, Ono T, Sakamoto K. Prostacyclin production in cultured endothelial cells is highly sensitive to low doses of ionizing radiation. Int J Radiat Biol. 1993;63:631–638. doi: 10.1080/09553009314450821CrossrefPubMedGoogle Scholar51.Soloviev AI, Tishkin SM, Parshikov AV, Ivanova IV, Goncharov EV, Gurney AM. Mechanisms of endothelial dysfunction after ionized radiation: selective impairment of the nitric oxide component of endothelium-dependent vasodilation. Br J Pharmacol. 2003;138:837–844. doi: 10.1038/sj.bjp.0705079CrossrefPubMedGoogle Scholar52.Lanza V, Fadda P, Iannone C, Negri R. Low-dose ionizing radiation stimulates transcription and production of endothelin by human vein endothelial cells. Radiat Res. 2007;168:193–198. doi: 10.1667/RR0780.1CrossrefPubMedGoogle Scholar53.Lanza V, Pretazzoli V, Olivieri G, Pascarella G, Panconesi A, Negri R. Transcriptional response of human umbilical vein endothelial cells to low doses of ionizing radiation. J Radiat Res. 2005;46:265–276. doi: 10.1269/jrr.46.265CrossrefPubMedGoogle Scholar54.Fardid R, Najafi M, Salajegheh A, Kazemi E, Rezaeyan A. Radiation-induced non-targeted effect in vivo: evaluation of cyclooygenase-2 and endothelin-1 gene expression in rat heart tissues. J Cancer Res Ther. 2017;13:51–55. doi: 10.4103/0973-1482.203601CrossrefPubMedGoogle Scholar55.Merlin SL, Brock GB, Begin LR, Hiou Tim FF, Macramalla AN, Seyam RM, Shenouda G, Dion SB. New insights into the role of endothelin-1 in radiation-associated impotence. Int J Impot Res. 2001;13:104–109. doi: 10.1038/sj.ijir.3900652CrossrefPubMedGoogle Scholar56.Papapetropoulos A, Burch SE, Topouzis S, Catravas JD. Radiation-induced alterations in angiotensin converting enzyme activity in cultured bovine pulmonary arterial endothelial cell monolayers. Toxicol Appl Pharmacol. 1993;120:96–105. doi: 10.1006/taap.1993.1091CrossrefPubMedGoogle Scholar57.Wei J, Xu H, Liu Y, Li B, Zhou F. Effect of captopril on radiation-induced TGF-β1 secretion in EA.Hy926 human umbilical vein endothelial cells. Oncotarget. 2017;8:20842–20850. doi: 10.18632/oncotarget.15356CrossrefPubMedGoogle Scholar58.Ward WF, Kim YT, Molteni A, Solliday NH. Radiation-induced pulmonary endothelial dysfunction in rats: modification by an inhibitor of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys. 1988;15:135–140. doi: 10.1016/0360-3016(88)90357-4CrossrefPubMedGoogle Scholar59.Cao S, Wu R. Expression of angiotensin II and aldosterone in radiation-induced lung injury. Cancer Biol Med. 2012;9:254–260. doi: 10.7497/j.issn.2095-3941.2012.04.006CrossrefPubMedGoogle Scholar60.Gajdusek CM, Tian H, London S, Zhou D, Rasey J, Mayberg MR. Gamma radiation effect on vascular smooth muscle cells in culture. Int J Radiat Oncol Biol Phys. 1996;36:821–828. doi: 10.1016/s0360-3016(96)00297-0CrossrefPubMedGoogle Scholar61.Keller PF, Verin V, Ziegler T, Mermillod B, Popowski Y, Delafontaine P. Gamma-irradiation markedly inhibits the hydrated collagen gel contradiction by arterial smooth muscle cells. J Investig Med. 2001;49:258–264. doi: 10.2310/6650.2001.33970CrossrefPubMedGoogle Scholar62.Heckenkamp J, Nigri GR, Waterman PR, Overhaus M, Kossodo SC, Lamuraglia GM. Gamma-irradiation modulates vascular smooth muscle cell and extracellular matrix function: implications for neointimal development. J Vasc Surg. 2004;39:1097–1103. doi: 10.1016/j.jvs.2003.12.021CrossrefPubMedGoogle Scholar63.Soloviev A, Tishkin S, Ivanova I, Zelensky S, Dosenko V, Kyrychenko S, Moreland RS. Functional and molecular consequences of ionizing irradiation on large conductance Ca2+-activated K+ channels in rat aortic smooth muscle cells. Life Sci. 2009;84:164–171. doi: 10.1016/j.lfs.2008.11.015CrossrefPubMedGoogle Scholar64.Soloviev AI, Tishkin SM, Zelensky SN, Ivanova IV, Kizub IV, Pavlova AA, Moreland RS. Ionizing radiation alters myofilament calcium sensitivity in vascular smooth muscle: potential role of protein kinase C. Am J Physiol Regul Integr Comp Physiol. 2005;289:R755–R762. doi: 10.1152/ajpregu.00748.2004CrossrefPubMedGoogle Scholar65.Roveri A, Coassin M, Maiorino M, Zamburlini A, van Amsterdam FT, Ratti E, Ursini F. Effect of hydrogen peroxide on calcium homeostasis in smooth muscle cells. Arch Biochem Biophys. 1992;297:265–270. doi: 10.1016/0003-9861(92)90671-iCrossrefPubMedGoogle Scholar66.Satoh K, Nigro P, Berk BC. Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin A. Antioxid Redox Signal. 2010;12:675–682. doi: 10.1089/ars.2009.2875CrossrefPubMedGoogle Scholar67.Ruef J, Rao GN, Li F, Bode C, Patterson C, Bhatnagar A, Runge MS. Induction of rat aortic smooth muscle cell growth by the lipid peroxidation product 4-hydroxy-2-nonenal. Circulation. 1998;97:1071–1078. doi: 10.1161/01.cir.97.11.1071CrossrefPubMedGoogle Scholar68.Rao GN, Alexander RW, Runge MS. Linoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-Fos, c-Jun, and c-Myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest. 1995;96:842–847. doi: 10.1172/JCI118130CrossrefPubMedGoogle Scholar69.Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, Valent P. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533–539. doi: 10.1002/ajh.22037CrossrefPubMedGoogle Scholar70.Dahlén T, Edgren G, Lambe M, Höglund M, Björkholm M, Sandin F, Själander A, Richter J, Olsson-Strömberg U, Ohm L, et al; Swedish CML Group and the Swedish CML Register Group. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med. 2016;165:161–166. doi: 10.7326/M15-2306CrossrefPubMedGoogle Scholar71.Saglio G, le Coutre P, Cortes J, Mayer J, Rowlings P, Mahon FX, Kroog G, Gooden K, Subar M, Shah NP. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Ann Hematol. 2017;96:1303–1313. doi: 10.1007/s00277-017-3012-zCrossrefPubMedGoogle Scholar72.Ali EA, Patel N, Khalid M, Kaddoura R, Kalavar M, Shani J, Yassin M. Myocardial infarction in chronic myeloid leukemia: results from the nationwide readmission database. Oncology (Huntingt). 2024;102:944–951. doi: 10.1159/000539149CrossrefGoogle Scholar73.Brümmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, Garcia-Gutierrez V, Chuah C, Kota V, Lipton JH, et al; BFORE study investigators. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36:1825–1833. doi: 10.1038/s41375-022-01589-yCrossrefPubMedGoogle Scholar74.Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, Smith BD, Ernst T, Giraldo-Castellano P, Olsson-Strömberg U, Saussele S, et al; BYOND Study Investigators. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34:2125–2137. doi: 10.1038/s41375-020-0915-9CrossrefPubMedGoogle Scholar75.Nicolini FE, Gagnieu M-C, Heiblig M, Blond E, Legros L, Guillermin Y, Morisset S, Barraco F, Etienne M, Le Borgne O, et al. Cardio-vascular events occurring on ponatinib in chronic phase chronic myeloid leukemia patients, preliminary analysis of a multicenter cohort. Blood. 2013;122:4020–4020. doi: 10.1182/blood.v122.21.4020.4020CrossrefGoogle Scholar76.Punwani N. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391:2275. doi: 10.1056/NEJMc2412813CrossrefPubMedGoogle Scholar77.Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617–626. doi: 10.1038/s41375-023-01829-9CrossrefPubMedGoogle Scholar78.Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, et al. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024;38:1522–1533. doi: 10.1038/s41375-024-02278-8CrossrefPubMedGoogle Scholar79.Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023;37:1048–1059. doi: 10.1038/s41375-023-01860-wCrossrefPubMedGoogle Scholar80.Luna A, Pérez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuño C, Vega MM, Alvarez-Larrán A, Salamanca A, García-Noblejas A, et al. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Ann Hematol. 2022;101:2263–2270. doi: 10.1007/s00277-022-04932-6CrossrefPubMedGoogle Scholar81.Pantaleo MA, Mandrioli A, Saponara M, Nannini M, Erente G, Lolli C, Biasco G. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012;12:231. doi: 10.1186/1471-2407-12-231CrossrefPubMedGoogle Scholar82.Cho JH, Won H, Lee W-S, Kim S-W, Hwang IG. Rapid progression of coronary atherosclerosis in patients taking an oral antitumor, multikinase receptor inhibitor. Circ Cardiovasc Interv. 2021;14:e010705. doi: 10.1161/CIRCINTERVENTIONS.121.010705CrossrefPubMedGoogle Scholar83.Sudasena D, Balanescu DV, Donisan T, Hassan S, Palaskas N, Kim P, Karimzad K, Lopez-Mattei J, Arain S, Gould KL, et al. Fulminant vascular and cardiac toxicity associated with tyrosine kinase inhibitor sorafenib. Cardiovasc Toxicol. 2019;19:382–387. doi: 10.1007/s12012-018-9499-2CrossrefPubMedGoogle Scholar84.Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142:2299–2311. doi: 10.1161/CIRCULATIONAHA.120.049981CrossrefPubMedGoogle Scholar85.Drobni ZD, Gongora C, Taron J, Suero-Abreu GA, Karady J, Gilman HK, Supraja S, Nikolaidou S, Leeper N, Merkely B, et al. Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer. J ImmunoTher Cancer. 2023;11:e007307. doi: 10.1136/jitc-2023-007307CrossrefPubMedGoogle Scholar86.Cheng SW, Ting AC, Ho P, Wu LL. Accelerated progression of carotid stenosis in patients with previous external neck irradiation. J Vasc Surg. 2004;39:409–415. doi: 10.1016/j.jvs.2003.08.031CrossrefPubMedGoogle Scholar87.Texakalidis P, Giannopoulos S, Tsouknidas I, Song S, Rivet DJ, Reiter ER, Reavey-Cantwell J. Prevalence of carotid stenosis following radiotherapy for head and neck cancer: a systematic review and meta-analysis. Head Neck. 2020;42:1077–1088. doi: 10.1002/hed.26102CrossrefPubMedGoogle Scholar88.Raghunathan D, Khilji MI, Hassan SA, Yusuf SW. Radiation-induced cardiovascular disease. Curr Atheroscler Rep. 2017;19:22. doi: 10.1007/s11883-017-0658-xCrossrefPubMedGoogle Scholar89.Pereira Lima MN, Biolo A, Foppa M, da Rosa PR, Rohde LE, Clausell N. A prospective, comparative study on the early effects of local and remote radiation therapy on carotid intima-media thickness and vascular cellular adhesion molecule-1 in patients with head and neck and prostate tumors. Radiother Oncol. 2011;101:449–453. doi: 10.1016/j.radonc.2010.03.026CrossrefPubMedGoogle Scholar90.Yakupovich A, Davison MA, Kharouta MZ, Turian J, Seder CW, Batus M, Fogg LF, Kalra D, Kosinski M, Taskesen T, et al. Heart dose and coronary artery calcification in patients receiving thoracic irradiation for lung cancer. J Thorac Dis. 2020;12:223–231. doi: 10.21037/jtd.2020.01.52CrossrefPubMedGoogle Scholar91.Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–998. doi: 10.1056/NEJMoa1209825CrossrefPubMedGoogle Scholar92.Abu Rmilah A, Adham A, Ikram-Ul H, Alzu’bi H, Nandan A, Jouni H, Hirashi S, Owen D, Deswal A, Lin SH, et al. Novel risk score for predicting acute cardiovascular and cerebrovascular events after chest radiotherapy in patients with breast or lung cancer [published online October 25, 2024]. Eur J Prev Cardiol. doi: 10.1093/eurjpc/zwae323. https://doi.org/10.1093/eurjpc/zwae323Google Scholar93.Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, et al. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 2017;31:2388–2397. doi: 10.1038/leu.2017.245CrossrefPubMedGoogle Scholar94.Maurizot A, Beressi JP, Manéglier B, de la Marre NH, Spentchian M, Soury P, Solvet-Sebire P, Collet-Gaudillat C, Baud JM, Livarek B, et al. Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion. Blood Cancer J. 2014;4:e247. doi: 10.1038/bcj.2014.66CrossrefPubMedGoogle Scholar95.Fuster JJ, Walsh K. Somatic mutations and clonal hematopoiesis: unexpected potential new drivers of age-related cardiovascular disease. Circ Res. 2018;122:523–532. doi: 10.1161/CIRCRESAHA.117.312115CrossrefPubMedGoogle Scholar96.Natarajan P, Jaiswal S, Kathiresan S. Clonal hematopoiesis: somatic mutations in blood cells and atherosclerosis. Circ Genom Precis Med. 2018;11:e001926. doi: 10.1161/CIRCGEN.118.001926CrossrefPubMedGoogle Scholar97.Ebert BL, Libby P. Clonal hematopoiesis confers predisposition to both cardiovascular disease and cancer: a newly recognized link between two major killers. Ann Intern Med. 2018;169:116–117. doi: 10.7326/M18-0737CrossrefPubMedGoogle Scholar98.Fernando F, Andres MS, Claudiani S, Kermani NZ, Ceccarelli G, Innes AJ, Khan A, Rosen SD, Apperley JF, Lyon AR, et al. Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score. Cardiooncology. 2024;10:42. doi: 10.1186/s40959-024-00245-xCrossrefPubMedGoogle Scholar99.Gover-Proaktor A, Granot G, Shapira S, Raz O, Pasvolsky O, Nagler A, Lev DL, Inbal A, Lubin I, Raanani P, et al. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma. 2017;58:1455–1467. doi: 10.1080/10428194.2016.1239258CrossrefPubMedGoogle Scholar100.Pinheiro EA, DeKeyser JM, Lenny B, Sapkota Y, Burridge PW. Nilotinib-induced alterations in endothelial cell function recapitulate clinical vascular phenotypes independent of ABL1. Sci Rep. 2024;14:7123. doi: 10.1038/s41598-024-57686-8CrossrefPubMedGoogle Scholar101.Detriche G, Zhang Y, Esposito B, Rea D, Messas E, Mirault T, Ait Oufella H. P3110Tyrosine kinase inhibitor nilotinib increases atherosclerosis burden in ApoE knock-out mice. Eur Heart J. 2019;40:ehz745.0185. doi: 10.1093/eurheartj/ehz745.0185CrossrefGoogle Scholar102.Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002;8:831–840. doi: 10.1038/nm731CrossrefPubMedGoogle Scholar103.Van der Veken B, De Meyer GRY, Martinet W. Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice. Vascul Pharmacol. 2018;100:34–40. doi: 10.1016/j.vph.2017.10.004CrossrefPubMedGoogle Scholar104.Newman JL, Stone JR. Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis. Cardiovasc Pathol. 2019;43:107148. doi: 10.1016/j.carpath.2019.107148CrossrefPubMedGoogle Scholar105.Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest. 2007;117:2974–2982. doi: 10.1172/JCI31344CrossrefPubMedGoogle Scholar106.Bu DX, Tarrio M, Maganto-Garcia E, Stavrakis G, Tajima G, Lederer J, Jarolim P, Freeman GJ, Sharpe AH, Lichtman AH. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:1100–1107. doi: 10.1161/ATVBAHA.111.224709CrossrefPubMedGoogle Scholar107.Weyand CM, Berry GJ, Goronzy JJ. The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease. J Leukoc Biol. 2018;103:565–575. doi: 10.1189/jlb.3MA0717-283CrossrefPubMedGoogle Scholar108.Ewing MM, Karper JC, Abdul S, de Jong RC, Peters HA, de Vries MR, Redeker A, Kuiper J, Toes RE, Arens R, et al. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int J Cardiol. 2013;168:1965–1974. doi: 10.1016/j.ijcard.2012.12.085CrossrefPubMedGoogle Scholar109.Matsumoto T, Sasaki N, Yamashita T, Emoto T, Kasahara K, Mizoguchi T, Hayashi T, Yodoi K, Kitano N, Saito T, et al. Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2016;36:1141–1151. doi: 10.1161/ATVBAHA.115.306848CrossrefPubMedGoogle Scholar110.Venkatesulu BP, Mahadevan LS, Aliru ML, Yang X, Bodd MH, Singh PK, Yusuf SW, Abe JI, Krishnan S. Radiation-induced endothelial vascular injury: a review of possible mechanisms. JACC Basic Transl Sci. 2018;3:563–572. doi: 10.1016/j.jacbts.2018.01.014CrossrefPubMedGoogle Scholar111.Stewart FA, Seemann I, Hoving S, Russell NS. Understanding radiation-induced cardiovascular damage and strategies for intervention. Clin Oncol (R Coll Radiol). 2013;25:617–624. doi: 10.1016/j.clon.2013.06.012CrossrefPubMedGoogle Scholar112.Stewart FA, Heeneman S, Te Poele J, Kruse J, Russell NS, Gijbels M, Daemen M. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE−/− mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. Am J Pathol. 2006;168:649–658. doi: 10.2353/ajpath.2006.050409CrossrefPubMedGoogle Scholar113.Hoving S, Heeneman S, Gijbels MJ, te Poele JA, Russell NS, Daemen MJ, Stewart FA. Single-dose and fractionated irradiation promote initiation and progression of atherosclerosis and induce an inflammatory plaque phenotype in ApoE(−/−) mice. Int J Radiat Oncol Biol Phys. 2008;71:848–857. doi: 10.1016/j.ijrobp.2008.02.031CrossrefPubMedGoogle Scholar114.Hoving S, Heeneman S, Gijbels MJ, te Poele JA, Pol JF, Gabriels K, Russell NS, Daemen MJ, Stewart FA. Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice. Radiother Oncol. 2011;101:100–108. doi: 10.1016/j.radonc.2011.09.019CrossrefPubMedGoogle Scholar115.Hoving S, Heeneman S, Gijbels MJ, te Poele JA, Bolla M, Pol JF, Simons MY, Russell NS, Daemen MJ, Stewart FA. NO-donating aspirin and aspirin partially inhibit age-related atherosclerosis but not radiation-induced atherosclerosis in ApoE null mice. PLoS One. 2010;5:e12874. doi: 10.1371/journal.pone.0012874CrossrefPubMedGoogle Scholar116.Patel DA, Kochanski J, Suen AW, Fajardo LF, Hancock SL, Knox SJ. Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation. Cancer. 2006;106:718–725. doi: 10.1002/cncr.21636CrossrefPubMedGoogle Scholar117.Brosius FC, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med. 1981;70:519–530. doi: 10.1016/0002-9343(81)90574-xCrossrefPubMedGoogle Scholar118.Virmani R, Farb A, Carter AJ, Jones RM. Pathology of radiation-induced coronary artery disease in human and pig. Cardiovasc Radiat Med. 1999;1:98–101. doi: 10.1016/s1522-1865(98)00010-9CrossrefPubMedGoogle Scholar119.Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol. 1996;27:766–773. doi: 10.1016/s0046-8177(96)90447-5CrossrefPubMedGoogle Scholar120.Christersdottir T, Pirault J, Gistera A, Bergman O, Gallina AL, Baumgartner R, Lundberg AM, Eriksson P, Yan ZQ, Paulsson-Berne G, et al. Prevention of radiotherapy-induced arterial inflammation by interleukin-1 blockade. Eur Heart J. 2019;40:2495–2503. doi: 10.1093/eurheartj/ehz206CrossrefPubMedGoogle Scholar121.Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, Soff G, Parameswaran R, Hassoun H. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29:3466–3473. doi: 10.1200/JCO.2011.35.5669CrossrefPubMedGoogle Scholar122.Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277–2285. doi: 10.1001/jama.2008.656CrossrefPubMedGoogle Scholar123.Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, Beckman JA, Harrison DG, Moslehi J. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018;71:e1–e8. doi: 10.1161/HYPERTENSIONAHA.117.10271CrossrefPubMedGoogle Scholar124.Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–1239. doi: 10.1093/jnci/djm086CrossrefPubMedGoogle Scholar125.Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018;12:409–425. doi: 10.1016/j.jash.2018.03.008CrossrefPubMedGoogle Scholar126.Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49:287–297. doi: 10.3109/02841860903524396CrossrefPubMedGoogle Scholar127.Chen XL, Lei YH, Liu CF, Yang QF, Zuo PY, Liu CY, Chen CZ, Liu YW. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One. 2013;8:e66721. doi: 10.1371/journal.pone.0066721CrossrefPubMedGoogle Scholar128.Chitkara A, Kaur N, Desai A, Mehta D, Anamika F, Sarkar S, Gowda N, Sethi P, Thawani R, Chen EY. Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: a systematic review and meta-analysis. Cancer Med. 2023;12:21579–21591. doi: 10.1002/cam4.6662CrossrefPubMedGoogle Scholar129.Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients. J Am Heart Assoc. 2017;6:e006278. doi: 10.1161/JAHA.117.006278CrossrefPubMedGoogle Scholar130.Qi WX, Shen Z, Tang LN, Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit Rev Oncol Hematol. 2014;92:71–82. doi: 10.1016/j.critrevonc.2014.04.004CrossrefPubMedGoogle Scholar131.Totzeck M, Mincu RI, Mrotzek S, Schadendorf D, Rassaf T. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol. 2018;25:482–494. doi: 10.1177/2047487318755193CrossrefPubMedGoogle Scholar132.Liu B, Ding F, Zhang D, Wei GH. Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis. Cancer Chemother Pharmacol. 2017;80:487–495. doi: 10.1007/s00280-017-3386-6CrossrefPubMedGoogle Scholar133.Saez Perdomo MN, Stuckey R, González-Pérez E, Sánchez-Sosa S, Estupiñan-Cabrera P, Lakhwani Lakhwani S, González San Miguel JD, Hernanz Soler N, Gordillo M, González Brito G, et al. The cardiovascular event risk associated with tyrosine kinase inhibitors and the lipid profile in patients with chronic myeloid leukemia. Hematol Rep. 2024;16:140–150. doi: 10.3390/hematolrep16010015CrossrefPubMedGoogle Scholar134.Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol. 2013;90:531–532. doi: 10.1111/ejh.12096CrossrefPubMedGoogle Scholar135.Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393–404. doi: 10.1182/blood-2016-09-739086CrossrefPubMedGoogle Scholar136.Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Sgherza N, Bonifacio M, et al. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematol Oncol. 2019;37:296–302. doi: 10.1002/hon.2606CrossrefPubMedGoogle Scholar137.Nichols ED, Jabbour E, Jammal N, Chew S, Bryan J, Issa G, Garcia-Manero G, Sasaki K, DiPippo A, Kantarjian H. Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. Am J Hematol. 2022;97:E350–E352. doi: 10.1002/ajh.26645CrossrefPubMedGoogle Scholar138.Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Morris MJ, Scardino PT, Eastham JA, Elkin EB. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer. 2012;118:3397–3406. doi: 10.1002/cncr.26623CrossrefPubMedGoogle Scholar139.Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, Ingelsson E, Lambe M, Stattin P, Holmberg L. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 2010;11:450–458. doi: 10.1016/S1470-2045(10)70038-3CrossrefPubMedGoogle Scholar140.Gupta D, Lee Chuy K, Yang JC, Bates M, Lombardo M, Steingart RM. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract. 2018;14:580–587. doi: 10.1200/JOP.18.00178CrossrefPubMedGoogle Scholar141.Aziz MK, Molony D, Monlezun D, Holder T, Brunckhorst O, Higgason N, Roland J, Magill R, Fatakdawala M, Iacobucci A, et al; European Association of Urology Prostate Cancer Guidelines Panel. Prostate cancer therapy cardiotoxicity map (PROXMAP) for advanced disease states: a systematic review and network meta-analysis with Bayesian modeling of treatment histories. Eur Urol. 2025;87:15–26. doi: 10.1016/j.eururo.2024.08.031CrossrefPubMedGoogle Scholar142.Hernandez RK, Sørensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer. 2009;115:4442–4449. doi: 10.1002/cncr.24508CrossrefPubMedGoogle Scholar143.Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab. 1995;80:3191–3195. doi: 10.1210/jcem.80.11.7593425CrossrefPubMedGoogle Scholar144.Khosrow-Khavar F, Filion KB, Al-Qurashi S, Torabi N, Bouganim N, Suissa S, Azoulay L. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017;28:487–496. doi: 10.1093/annonc/mdw673CrossrefPubMedGoogle Scholar145.Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G, Moslehi J. Cardiovascular complications of novel multiple myeloma treatments. Circulation. 2016;133:908–912. doi: 10.1161/CIRCULATIONAHA.115.018351CrossrefPubMedGoogle Scholar146.Ma Z, Sun X, Zhang Y, Li H, Sun D, An Z, Zhang Y. Risk of thromboembolic events in cancer patients treated with immune checkpoint inhibitors: a meta-analysis of randomized controlled trials. Thromb Haemost. 2022;122:1757–1766. doi: 10.1055/s-0042-1749185CrossrefPubMedGoogle Scholar147.Khorana AA, Palaia J, Rosenblatt L, Pisupati R, Huang N, Nguyen C, Barron J, Gallagher K, Bond TC. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer. J ImmunoTher Cancer. 2023;11:e006072. doi: 10.1136/jitc-2022-006072CrossrefPubMedGoogle Scholar148.Overvad TF, Skjøth F, Piazza G, Noble S, Ording AG, Larsen TB, Nielsen PB. The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: a Danish cohort study. J Thromb Haemost. 2022;20:2921–2929. doi: 10.1111/jth.15883CrossrefPubMedGoogle Scholar149.Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20:1370–1385. doi: 10.1016/S1470-2045(19)30413-9CrossrefPubMedGoogle Scholar150.Bindal P, Patell R, Chiasakul T, Lauw MN, Ko A, Wang TF, Zwicker JI. A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost. 2024;22:2071–2080. doi: 10.1016/j.jtha.2024.03.021CrossrefPubMedGoogle Scholar151.Tanimura K, Otake H, Kawamori H, Toba T, Nagasawa A, Nakano S, Takahashi Y, Fukuyama Y, Kozuki A, Shite J, et al. Morphological plaque characteristics and clinical outcomes in patients with acute coronary syndrome and a cancer history. J Am Heart Assoc. 2021;10:e020243. doi: 10.1161/JAHA.120.020243CrossrefPubMedGoogle Scholar152.Wang C, Tian X, Feng X, Demuyakor A, Hu S, Wang Y, Li L, Cui L, Dong F, Dai J, et al. Pancoronary plaque characteristics and clinical outcomes in acute coronary syndrome patients with cancer history. Atherosclerosis. 2023;378:117118. doi: 10.1016/j.atherosclerosis.2023.03.023CrossrefPubMedGoogle Scholar153.Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114:1852–1866. doi: 10.1161/CIRCRESAHA.114.302721CrossrefPubMedGoogle Scholar154.McElroy M, Kim Y, Niccoli G, Vergallo R, Langford-Smith A, Crea F, Gijsen F, Johnson T, Keshmiri A, White SJ. Identification of the haemodynamic environment permissive for plaque erosion. Sci Rep. 2021;11:7253. doi: 10.1038/s41598-021-86501-xCrossrefPubMedGoogle Scholar155.Meteva D, Vinci R, Seppelt C, Abdelwahed YS, Pedicino D, Nelles G, Skurk C, Haghikia A, Rauch-Kröhnert U, Gerhardt T, et al. Toll-like receptor 2, hyaluronan, and neutrophils play a key role in plaque erosion: the OPTICO-ACS study. Eur Heart J. 2023;44:3892–3907. doi: 10.1093/eurheartj/ehad379CrossrefPubMedGoogle Scholar156.Yoo J, Kwon I, Kim S, Kim HM, Kim YD, Nam HS, Heo JH. Coagulation factor expression and composition of arterial thrombi in cancer-associated stroke. Stroke. 2023;54:2981–2989. doi: 10.1161/STROKEAHA.123.044910CrossrefPubMedGoogle Scholar157.Bang OY, Chung JW, Cho YH, Oh MJ, Seo WK, Kim GM, Ahn MJ. Circulating DNAs, a marker of neutrophil extracellular traposis and cancer-related stroke: the OASIS-cancer study. Stroke. 2019;50:2944–2947. doi: 10.1161/STROKEAHA.119.026373CrossrefPubMedGoogle Scholar158.Demers M, Wong SL, Martinod K, Gallant M, Cabral JE, Wang Y, Wagner DD. Priming of neutrophils toward NETosis promotes tumor growth. Oncoimmunology. 2016;5:e1134073. doi: 10.1080/2162402X.2015.1134073CrossrefPubMedGoogle Scholar159.Galgano L, Guidetti GF, Torti M, Canobbio I. The controversial role of LPS in platelet activation in vitro. Int J Mol Sci. 2022;23:10900. doi: 10.3390/ijms231810900CrossrefPubMedGoogle Scholar160.Su X, Brassard A, Bartolomucci A, Dhoparee-Doomah I, Qiu Q, Tsering T, Rohanizadeh R, Koufos O, Giannias B, Bourdeau F, et al. Tumour extracellular vesicles induce neutrophil extracellular traps to promote lymph node metastasis. J Extracell Vesicles. 2023;12:e12341. doi: 10.1002/jev2.12341CrossrefPubMedGoogle Scholar161.Bang OY, Chung JW, Lee MJ, Kim SJ, Cho YH, Kim GM, Chung CS, Lee KH, Ahn MJ, Moon GJ. Cancer cell-derived extracellular vesicles are associated with coagulopathy causing ischemic stroke via tissue factor-independent way: the OASIS-CANCER study. PLoS One. 2016;11:e0159170. doi: 10.1371/journal.pone.0159170CrossrefPubMedGoogle Scholar162.Leal AC, Mizurini DM, Gomes T, Rochael NC, Saraiva EM, Dias MS, Werneck CC, Sielski MS, Vicente CP, Monteiro RQ. Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancer-associated thrombosis. Sci Rep. 2017;7:6438. doi: 10.1038/s41598-017-06893-7CrossrefPubMedGoogle Scholar163.Dudiki T, Veleeparambil M, Zhevlakova I, Biswas S, Klein EA, Ford P, Podrez EA, Byzova TV. Mechanism of tumor-platelet communications in cancer. Circ Res. 2023;132:1447–1461. doi: 10.1161/CIRCRESAHA.122.321861CrossrefPubMedGoogle Scholar164.Shindo K, Aishima S, Ohuchida K, Fujiwara K, Fujino M, Mizuuchi Y, Hattori M, Mizumoto K, Tanaka M, Oda Y. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol Cancer. 2013;12:168. doi: 10.1186/1476-4598-12-168CrossrefPubMedGoogle Scholar165.Woei-A-Jin FJ, Tesselaar ME, Garcia Rodriguez P, Romijn FP, Bertina RM, Osanto S. Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis? Br J Cancer. 2016;115:332–338. doi: 10.1038/bjc.2016.170CrossrefPubMedGoogle Scholar166.Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018;10:380. doi: 10.3390/cancers10100380CrossrefPubMedGoogle Scholar167.Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol. 2018;72:89–93. doi: 10.1016/j.jjcc.2018.02.011CrossrefPubMedGoogle Scholar168.Geddings JE, Hisada Y, Boulaftali Y, Getz TM, Whelihan M, Fuentes R, Dee R, Cooley BC, Key NS, Wolberg AS, et al. Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost. 2016;14:153–166. doi: 10.1111/jth.13181CrossrefPubMedGoogle Scholar169.Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, Baker CH, Francis JL. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost. 2008;6:1517–1524. doi: 10.1111/j.1538-7836.2008.02987.xCrossrefPubMedGoogle Scholar170.Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, Hostetter G, Harvey J, Taubman MB. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13:2870–2875. doi: 10.1158/1078-0432.CCR-06-2351CrossrefPubMedGoogle Scholar171.Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol. 2009;27:4834–4838. doi: 10.1200/JCO.2009.22.6324CrossrefPubMedGoogle Scholar172.Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105:1734–1741. doi: 10.1182/blood-2004-05-2042CrossrefPubMedGoogle Scholar173.Regina S, Valentin JB, Lachot S, Lemarié E, Rollin J, Gruel Y. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem. 2009;55:1834–1842. doi: 10.1373/clinchem.2009.123695CrossrefPubMedGoogle Scholar174.Falanga A, Marchetti M, Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res. 2015;135(Suppl 1):S8–S11. doi: 10.1016/S0049-3848(15)50432-5CrossrefPubMedGoogle Scholar175.Nasser NJ, Fox J, Agbarya A. Potential mechanisms of cancer-related hypercoagulability. Cancers (Basel). 2020;12:566. doi: 10.3390/cancers12030566CrossrefPubMedGoogle Scholar176.Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015;3:83–92. doi: 10.2147/HP.S93413CrossrefPubMedGoogle Scholar177.Di Virgilio F, Adinolfi E. Extracellular purines, purinergic receptors and tumor growth. Oncogene. 2017;36:293–303. doi: 10.1038/onc.2016.206CrossrefPubMedGoogle Scholar178.Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70:926–938. doi: 10.1016/j.jacc.2017.06.047CrossrefPubMedGoogle Scholar179.Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, Panageas KS, DeAngelis LM. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2019;133:781–789. doi: 10.1182/blood-2018-06-860874CrossrefPubMedGoogle Scholar180.Wang J, Kim YD, Kim CH. Incidence and risk of various types of arterial thromboembolism in patients with cancer. Mayo Clin Proc. 2021;96:592–600. doi: 10.1016/j.mayocp.2020.05.045CrossrefPubMedGoogle Scholar181.Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, van den Berg MP, Burgerhof JG, Hoekstra HJ, Sluiter WJ, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 2004;40:701–706. doi: 10.1016/j.ejca.2003.12.012CrossrefPubMedGoogle Scholar182.Kim AS, Khorana AA, McCrae KR. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res. 2020;225:33–53. doi: 10.1016/j.trsl.2020.06.012CrossrefPubMedGoogle Scholar183.Chen N, Ren M, Li R, Deng X, Li Y, Yan K, Xiao L, Yang Y, Wang L, Luo M, et al. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma. Mol Cancer. 2015;14:140. doi: 10.1186/s12943-015-0418-xCrossrefPubMedGoogle Scholar184.Pouwer MG, Pieterman EJ, Verschuren L, Caspers MPM, Kluft C, Garcia RA, Aman J, Jukema JW, Princen HMG. The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model. Front Cardiovasc Med. 2018;5:55. doi: 10.3389/fcvm.2018.00055CrossrefPubMedGoogle Scholar185.Merkulova A, Mitchell SC, Stavrou EX, Forbes GL, Schmaier AH. Ponatinib treatment promotes arterial thrombosis and hyperactive platelets. Blood Adv. 2019;3:2312–2316. doi: 10.1182/bloodadvances.2019000034CrossrefPubMedGoogle Scholar186.Aguila S, Cuenca EJ, Lys MJ, Garcia-Hernandez C, Fernández MJ, Noya M, García Gutiérrez V, Palomera L, Senín A, Perez Lopez R, et al. Thrombogenesis mechanisms of high doses of ponatinib in patients with Chronic Myeloid Leukemia (CML) compared to tyrosine kinase inhibitors. Blood. 2022;140:6730–6732. doi: 10.1182/blood-2022-163070CrossrefGoogle Scholar187.Telerman A, Granot G, Leibovitch C, Yarchovsky-Dolberg O, Shacham-Abulafia A, Partouche S, Yeshurun M, Ellis MH, Raanani P, Wolach O. Neutrophil extracellular traps are increased in chronic myeloid leukemia and are differentially affected by tyrosine kinase inhibitors. Cancers (Basel). 2021;14:119. doi: 10.3390/cancers14010119CrossrefPubMedGoogle Scholar188.Stepanian A, Travers RJ, Tesfu A, Wolter NL, Man JJ, Lu Q, Shamsuzzaman S, Deaton RA, Owens GK, Chen CS, et al. Ponatinib, but not the new Abl-kinase inhibitor asciminib, activates platelets, leukocytes, and endothelial cell TNF signaling to induce atherosclerotic plaque inflammation, myocardial infarction, and stroke. Circulation. 2025;152:765–783. doi: 10.1161/CIRCULATIONAHA.125.073610CrossrefPubMedGoogle Scholar189.Rühl H, Schröder L, Müller J, Fimmers R, Sukhitashvili S, Welz J, Kuhn WC, Oldenburg J, Rudlowski C, Pötzsch B. Tamoxifen induces resistance to activated protein C. Thromb Res. 2014;133:886–891. doi: 10.1016/j.thromres.2014.02.004CrossrefPubMedGoogle Scholar190.Ceschi A, Noseda R, Palin K, Verhamme K. Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database. Front Pharmacol. 2020;11:557. doi: 10.3389/fphar.2020.00557CrossrefPubMedGoogle Scholar191.Cánovas MS, Garay DF, Moran LO, Pérez JR, Rubio CMG, de Mena ML, Portero BO, Castro JB, Lage Y, Lavin DC, et al. Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group. Clin Transl Oncol. 2022;24:2010–2020. doi: 10.1007/s12094-022-02860-5CrossrefPubMedGoogle Scholar192.Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol. 2008;103:398–406. doi: 10.1007/s00395-008-0733-0CrossrefPubMedGoogle Scholar193.Youssef A, Kasso N, Torloni AS, Stanek M, Dragovich T, Gimbel M, Mahmoud F. Thrombotic thrombocytopenic purpura due to checkpoint inhibitors. Case Rep Hematol. 2018;2018:2464619. doi: 10.1155/2018/2464619CrossrefPubMedGoogle Scholar194.Fonkalsrud EW, Sanchez M, Zerubavel R, Mahoney A. Serial changes in arterial structure following radiation therapy. Surg Gynecol Obstet. 1977;145:395–400.PubMedGoogle Scholar195.Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, Dimmeler S, Zeiher AM. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111:2981–2987. doi: 10.1161/CIRCULATIONAHA.104.504340CrossrefPubMedGoogle Scholar196.Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1–E7. doi: 10.1161/hh1301.093953CrossrefPubMedGoogle Scholar197.Wong M, Grossman J, Hahn BH, La Cava A. Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin Immunol. 2008;129:3–9. doi: 10.1016/j.clim.2008.07.001CrossrefPubMedGoogle Scholar198.Kulkarni U, Nayak V, Prabhu MM, Rao R. Tamoxifen-induced vasculitis. J Oncol Pharm Pract. 2020;26:735–737. doi: 10.1177/1078155219862342CrossrefPubMedGoogle Scholar199.Fukui M, Shiraishi K, Yoshida S, Yatsuzuka K, Matsumoto T, Sayama K. Olaparib-induced cutaneous vasculitis in a patient with recurrent ovarian cancer. Eur J Dermatol. 2022;32:655–656. doi: 10.1684/ejd.2022.4343CrossrefPubMedGoogle Scholar200.Bock VL, Friedlander M, Waring D, Kossard S, Wood GK. Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. Australas J Dermatol. 2014;55:282–285. doi: 10.1111/ajd.12110CrossrefPubMedGoogle Scholar201.Muzzana M, Pedrazzoli P, Lasagna A. G-CSF and G-CSF-related vasculitis: a systematic review of the literature and intriguing future research perspectives. Future Oncol. 2021;17:4619–4634. doi: 10.2217/fon-2021-0701CrossrefPubMedGoogle Scholar202.Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol. 2018;14:569–579. doi: 10.1038/s41584-018-0074-9CrossrefPubMedGoogle Scholar203.Lee CM, Wang M, Rajkumar A, Calabrese C, Calabrese L. A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: unraveling the complexities at the intersection of immunology and vascular pathology. Semin Arthritis Rheum. 2024;66:152440. doi: 10.1016/j.semarthrit.2024.152440CrossrefPubMedGoogle Scholar204.Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, Judge A, Hutchings A, Merkel PA, Luqmani RA, et al; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Arthritis Rheumatol. 2022;74:400–406. doi: 10.1002/art.41983CrossrefPubMedGoogle Scholar205.Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579–1589. doi: 10.1016/S1470-2045(18)30608-9CrossrefPubMedGoogle Scholar206.Zhang H, Watanabe R, Berry GJ, Vaglio A, Liao YJ, Warrington KJ, Goronzy JJ, Weyand CM. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci USA. 2017;114:E970–E979. doi: 10.1073/pnas.1616848114CrossrefPubMedGoogle Scholar207.Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018;37:2579–2584. doi: 10.1007/s10067-018-4177-0CrossrefPubMedGoogle Scholar208.Aya F, Ruiz-Esquide V, Viladot M, Font C, Prieto-González S, Prat A, Arance A. Vasculitic neuropathy induced by pembrolizumab. Ann Oncol. 2017;28:433–434. doi: 10.1093/annonc/mdw613CrossrefPubMedGoogle Scholar209.Cheng C, Nguyen MN, Nayernama A, Jones SC, Brave M, Agrawal S, Amiri-Kordestani L, Woronow D. Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: a review of cases reported to the FDA Adverse Event Reporting System and published in the literature. Vasc Med. 2021;26:526–534. doi: 10.1177/1358863X211006470CrossrefPubMedGoogle Scholar210.Guyon J, Gouverneur A, Maumus-Robert S, Bérard X, Pariente A, Bikfalvi A, Noize P. Association between antiangiogenic drugs used for cancer treatment and artery dissections or aneurysms. JAMA Oncol. 2021;7:775–778. doi: 10.1001/jamaoncol.2021.0210CrossrefPubMedGoogle Scholar211.Wang S, Chen M, Zhang X, Zhang L, Jia M, Shen Z, Wang J, Zhao B, Gong Y, Gong J. Aneurysm and artery dissection following the use of vascular endothelial growth factor inhibitor: a real-world analysis using a spontaneous reporting system. J Am Heart Assoc. 2021;10:e020844. doi: 10.1161/JAHA.121.020844CrossrefPubMedGoogle Scholar212.Oshima Y, Tanimoto T, Yuji K, Tojo A. Association between aortic dissection and systemic exposure of vascular endothelial growth factor pathway inhibitors in the Japanese adverse drug event report database. Circulation. 2017;135:815–817. doi: 10.1161/CIRCULATIONAHA.116.025144CrossrefPubMedGoogle Scholar213.Kang S, Yeon B, Kim MS, Yoo M, Kim B, Yu YM. Aneurysm and artery dissection after oral VEGFR-TKI use in adults with cancer. JAMA Netw Open. 2023;6:e2345977. doi: 10.1001/jamanetworkopen.2023.45977CrossrefPubMedGoogle Scholar214.Wu CW, Huang HY, Lin SY, Wang CC, Huang CF, Wu IH. Vascular endothelial growth factor inhibitors and the risk of aortic aneurysm and aortic dissection. JAMA Netw Open. 2024;7:e240940. doi: 10.1001/jamanetworkopen.2024.0940CrossrefPubMedGoogle Scholar215.Balanescu DV, Bloomingdale R, Donisan T, Yang EH, Parwani P, Iliescu C, Herrmann J, Hanson I. Mechanisms of myocardial ischemia in cancer patients: a state-of-the-art review of obstructive versus non-obstructive causes. Rev Cardiovasc Med. 2022;23:227. doi: 10.31083/j.rcm2307227CrossrefPubMedGoogle Scholar216.Panday P, Hausvater A, Pleasure M, Smilowitz NR, Reynolds HR. Cancer and myocardial infarction in women. Am J Cardiol. 2023;194:27–33. doi: 10.1016/j.amjcard.2023.02.007CrossrefPubMedGoogle Scholar217.Peng X, Zhu Z, Tang J, Zhou S. Spontaneous coronary artery dissection accompanied with antiphospholipid syndrome and leukemia. Int Heart J. 2018;59:891–894. doi: 10.1536/ihj.17-462CrossrefPubMedGoogle Scholar218.Kavyani R, Salari S, Norozi Z, Hosseini S, Abdi S, Rai A, Maleki M. Left main and three vessels spontaneous coronary artery dissection as an incidental finding in young man with history of Hodgkin’s lymphoma-a case report. BMC Cardiovasc Disord. 2024;24:14. doi: 10.1186/s12872-023-03609-wCrossrefPubMedGoogle Scholar219.Karabay CY, Biteker M, Zehir R, Bezgin T, Tanboga H, Can MM, Güler A, Duran NE, Ozkan M. Multiple spontaneous coronary artery dissection associated with Trousseau’s syndrome. Cardiol J. 2010;17:625–627.PubMedGoogle Scholar220.Hart K, Patel S, Kovoor J. Spontaneous coronary artery dissection associated with anal cancer management with fluorouracil and radiotherapy. Cureus. 2019;11:e4979. doi: 10.7759/cureus.4979CrossrefPubMedGoogle Scholar221.Saffar H, Abdan L, Abdan Z, Hekmat H, Amirzadegan A, Omidi N. Spontaneous coronary artery dissection in the context of tamoxifen; Is there any correlation? Clin Case Rep. 2024;12:e9140. doi: 10.1002/ccr3.9140CrossrefPubMedGoogle Scholar222.Gilyarov MY, Rozhkov A, Selyutskii S. Spontaneous dissection of coronary arteries in patients receiving combined antitumor therapy with cisplatin and capecitabine. Emerg. Cardiol. 2014;2:28–34.Google Scholar223.Mir MA, Patnaik MM, Herrmann J. Spontaneous coronary artery dissection during hematopoietic stem cell infusion. Blood. 2013;122:3388–3389. doi: 10.1182/blood-2013-09-528760CrossrefPubMedGoogle Scholar224.Donisan T, Herrmann J, Gulati R, Alkhouli MA, Hampel P, Borlaug B. Multivessel spontaneous coronary artery dissections associated with acalabrutinib. J Am Coll Cardiol. 2023;81:3331–3331. doi: 10.1016/s0735-1097(23)03775-0CrossrefGoogle Scholar225.Xu B, Iida Y, Glover KJ, Ge Y, Wang Y, Xuan H, Hu X, Tanaka H, Wang W, Fujimura N, et al. Inhibition of VEGF (vascular endothelial growth factor)-A or its receptor activity suppresses experimental aneurysm progression in the aortic elastase infusion model. Arterioscler Thromb Vasc Biol. 2019;39:1652–1666. doi: 10.1161/ATVBAHA.119.312497CrossrefPubMedGoogle Scholar226.Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Lond). 2016;16:481–485. doi: 10.7861/clinmedicine.16-5-481CrossrefPubMedGoogle Scholar227.Dai S, Zhong Y, Cui H, Zhao J, Li S. Aortic dissection induced by vascular endothelial growth factor inhibitors. Front Pharmacol. 2023;14:1189910. doi: 10.3389/fphar.2023.1189910CrossrefPubMedGoogle Scholar228.Hayes SN, Tweet MS, Adlam D, Kim ESH, Gulati R, Price JE, Rose CH. Spontaneous coronary artery dissection: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76:961–984. doi: 10.1016/j.jacc.2020.05.084CrossrefPubMedGoogle Scholar229.Cortes J, Saura C, Atzori F. Risk of venous thromboembolism with bevacizumab in cancer patients. JAMA. 2009;301:1434–5, author reply 1435. doi: 10.1001/jama.2009.440CrossrefPubMedGoogle Scholar230.Minor DR. Risk of venous thromboembolism with bevacizumab in cancer patients. JAMA. 2009;301:1434. doi: 10.1001/jama.2009.439CrossrefPubMedGoogle Scholar231.Minor DR. Risk of arterial thrombosis not increased by sorafenib or sunitinib. J Clin Oncol. 2010;28:e619; author reply e620. doi: 10.1200/JCO.2010.31.0219CrossrefPubMedGoogle Scholar
Advertisement
RecommendedMarch 2016Vascular Toxicities of Cancer Therapies
Joerg Herrmann,
Eric H. Yang,
Cezar A. Iliescu,
Mehmet Cilingiroglu,
Konstantinos Charitakis,
Abdul Hakeem,
Konstantinos Toutouzas,
Massoud A. Leesar,
Cindy L. Grines, and
[...]Konstantinos Marmagkiolis
+6 authors
February 2021Cancer Therapy–Associated Thrombosis
Steven P. Grover,
Yohei M. Hisada,
Raj S. Kasthuri,
Brandi N. Reeves, and
[...]Nigel Mackman
+1 authors
March 2022Association Between Radiotherapy and Death From Cardiovascular Disease Among Patients With Cancer: A Large Population‐Based Cohort Study
Enrui Liu,
Xu Guan,
Ran Wei,
Zheng Jiang,
Zheng Liu,
Guiyu Wang,
Yinggang Chen, and
[...]Xishan Wang
+4 authors
Advertisement
Submit a Response to This ArticleCloseCompose eLetterTitle:Comment text:Contributors(all fields are required)Remove ContributorFirst Name:Last Name:Email:Affiliation:Add Another Contributor
Statement of Competing InterestsCompeting Interests?YESNOPlease describe the competing interests
CancelSubmitView full text|Download PDF
Comment Response
Arteriosclerosis, Thrombosis, and Vascular Biology
Submit
Browse
Browse
Collections
Subject Terms
AHA Journal Podcasts
Trend Watch
Resources
Resources
CME
Journal Metrics
Early Career Resources
AHA Journals @ Meetings
Information
Information
For Authors
For Reviewers
For Subscribers
For International Users
Arteriosclerosis, Thrombosis, and Vascular Biology
Circulation
Circulation Research
Hypertension
Stroke
Journal of the American Heart Association
Circulation: Arrhythmia and Electrophysiology
Circulation: Cardiovascular Imaging
Circulation: Cardiovascular Interventions
Circulation: Population Health and Outcomes
Circulation: Genomic and Precision Medicine
Circulation: Heart Failure
Stroke: Vascular and Interventional Neurology
Annals of Internal Medicine: Clinical Cases
This page is managed by Wolters Kluwer Health, Inc. and/or its affiliates or subsidiaries. Wolters Kluwer Privacy Policy
Your California Privacy Choices
Manage Cookie Preferences
Back to top
National Center
7272 Greenville Ave.Dallas, TX 75231Customer Service
1-800-AHA-USA-1
1-800-242-8721Hours
Monday - Friday: 7 a.m. – 7 p.m. CT
Saturday: 9 a.m. - 5 p.m. CT
Closed on SundaysTax Identification Number
13-5613797
ABOUT
US
About the
AHA/ASA
Annual
report
AHA Financial
Information
Careers
International
Programs
Latest Heart and
Stroke News
AHA/ASA Media
Newsroom
GET
INVOLVED
Donate
Advocate
Volunteer
ShopHeart
ShopCPR
OUR
SITES
American Heart
Association
American Stroke
Association
CPR &
ECC
Go Red For
Women
More
Sites
AHA Careers
AHA Privacy Policy
Medical Advice Disclaimer
Copyright Policy
Accessibility Statement
Ethics Policy
Conflict of Interes Policy
Linking Policy
Whistleblower Policy
Content Editorial Guidelines
Diversity
Suppliers & Providers
State Fundraising Notices
©2026 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.The
American Heart Association is a qualified 501(c)(3) tax-exempt organization.*Red Dress ™ DHHS, Go Red ™
AHA ; National Wear Red Day® is a registered trademark.
Copy link✓Thanks for sharing!Find any serviceAddToAnyMore…Privacy Preference CenterWhen you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device. Because we respect your right to privacy, you can choose not to allow certain types of cookies on our website. Click on the different category headings to find out more and manage your cookie preferences. However, blocking some types of cookies may impact your experience on the site and the services we are able to offer.
Privacy & Cookie NoticeManage Consent PreferencesStrictly Necessary CookiesAlways ActiveThese cookies are necessary for the website to function. They are usually set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, this may have an effect on the proper functioning of (parts of) the site.View Vendor Details‎Functional Cookies
Functional Cookies These cookies enable the website to provide enhanced functionality, user experience and personalization, and may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies, then some or all of these services may not function properly.View Vendor Details‎Performance Cookies
Performance Cookies These cookies support analytic services that measure and improve the performance of our site. They
help us know which pages are the most and least popular and see how visitors move around the site.View Vendor Details‎Advertising Cookies
Advertising Cookies These cookies may collect insights to issue personalized content and advertising on our own and other websites, and may be set through our site by third party providers.
If you do not allow these cookies, you may still see basic advertising on your browser that is generic and not based on your interests.View Vendor Details‎Back ButtonVendors List Search IconFilter IconClear checkbox label labelApply CancelConsent Leg.Interest checkbox label label checkbox label label checkbox label labelAllow AllReject All Confirm My Choices
Now Reading:Vascular Toxicities of Cancer Therapies: 2025 UpdateTrack CitationsAdd to favoritesShareGet AccessPREVIOUS ARTICLECytosolic Versus Lysosomal Lipolysis in Adipose Tissue: Opposing Roles in Cardiometabolic DiseasePreviousNEXT ARTICLECardiovascular Manifestations and Immunobiology of SarcoidosisNext__("articleCrossmark.closePopup")
